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ABSTRACT 
 
Introduction 
Large Granular Lymphocytes (LGLs) leukemia (LGLL) is a chronic lymphoproliferation of 
clonal cytotoxic LGLs, which can be divided in two different subsets, based on Cluster of 
Differentiation (CD)-3 expression: CD3- Natural Killer (NK) cells and CD3+ (CD8+/CD4- or 
CD8-/dim/CD4+) T-LGLs.  
Leukemic LGLs are characterized by the up-regulation of several pro-survival signaling 
pathways. Among these, the most relevant is the JAK-STAT axis, whose constitutive 
activation is in part explained by somatic activating mutations in STAT3 and STAT5b.  
Neutropenia is the most frequent clinical manifestation. Despite being so common, its 
pathogenesis has not been well established yet, although high levels of soluble Fas 
Ligand (sFasL) were detected in serum of LGLL patients and supposed to trigger 
neutrophil’s death. 
Aims 
This work aimed i) to describe the distinctive biological features of T-LGLs or NK cells of 
neutropenic LGLL patients; ii) to investigate the role of microRNAs in the regulation of 
FasL expression in leukemic LGLs.  
Methods 
LGLs were purified by FACSAriaIII cell sorter from peripheral blood mononuclear cells 
(PBMCs) of untreated LGLL patients and their immunophenotype was evaluated by Flow 
Cytometry. The screening of STATs mutations was performed by Sanger sequencing. 
PBMCs of patients were cultured in vitro and STAT3 transcriptional activity were 
inhibited or triggered with Stattic or IL-6, respectively. Transcriptional and protein 
expression levels were evaluated by Real Time-PCR, Western Blot (WB) assays and ELISA 
test.  
High throughput and single miRNA analysis were carried out on purified T-LGLs by using 
the TaqMan® Human microRNA Array and Assays, respectively. Transfection with miR-
146b mimic was performed using the Amaxa Nucleofactor and the Ingenio 
Electroporation Solution. 
 
 
4 
 
Results 
We showed that leukemic T-LGLs of neutropenic patients were characterized by an 
immunophenotypic signature (CD3+/CD8+/CD16+/CD56- phenotype) and by higher 
STAT3 activations, higher incidence of STAT3 mutations and higher levels of sFasL, 
compared to T-LGLs of non-neutropenic patients. We also demonstrated that FasL 
transcription was mediated by STAT3 activation in T-LGLL patients.  
The characterization of neutropenic CLPD-NK patients, instead, showed that they were 
characterized by CD56-/dim/CD16high/CD57- cytotoxic NK cells expansion. However, we 
observed a heterogeneous level of STAT3 activation and a heterogeneous expression of 
FasL in this subset of patients. 
To investigate whether STAT3 could play its pathogenetic role through an altered 
expression of microRNAs, we studied miRNAs differentially expressed in patients 
characterized by neutropenia as compared to those with normal absolute neutrophil 
count (ANC). We showed that miR-146b expression, found down-regulated in 
neutropenic patients, was correlated with the ANC of T-LGLL patients.  
To investigate miR-146b role in neutropenia development, we transfected purified CD8+ 
T-LGLs with a miR-146b mimic. We showed that restoration of miR-146b led to a 
decrease of FasL mRNA, without changes in the FasL primary transcript, as compared to 
control. However, FasL was not identified among the putative miR-146b target genes, 
suggesting that miR-146b could regulate FasL expression indirectly. Therefore, we 
checked for genes involved in mRNA stability and we found that the defective miR-146b 
expression lead to increased transcriptional levels of the mRNA stabilizer HuR, that is 
required for FasL expression in T-lymphocytes. Consistently, by WB assays, we 
demonstrated that in T-LGLs of neutropenic patients HuR endogenous protein levels 
were higher than in T-LGLs of non-neutropenic ones. HuR-mediated FasL mRNA 
stabilization explained the increased FasL expression observed in neutropenic patients. 
Conclusions 
In this work we identify distinctive features of neutropenic LGLL patients, that could 
acquire relevance to correctly address the management of each patient, and we identify 
a miR-146b-FasL axis involved in neutropenia development in leukemic T-LGLs. 
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1. INTRODUCTION 
 
1.1. Large Granular Lymphocytes 
Large Granular Lymphocytes (LGLs) belong to the lymphoid lineage of hematopoietic 
cells and are mature post-thymic lymphocytes [1,2]. In normal adults, LGLs account for 
5% to 15% of peripheral blood mononuclear cells (PBMCs) and their normal range is 
around 0.2-0.4 x109/L [3].   
These cells are characterized by a distinct morphology (Figure 1): large size (15-18 m), 
a round or reniform nucleus and an abundant cytoplasm with typical azurophilic 
granules, containing cytolytic components (such as perforin and granzymes B), which 
represent a cytotoxic equipment that allows LGLs to exert cytotoxic functions and, 
therefore, to play a central role in cell-mediated immune response [4]. 
 
Figure 1.1. May-Grünwald-Giemsa staining of a large granular lymphocyte in peripheral blood: 
cytoplasmatic granules, in dark purple, are clearly visible. 
 
LGLs can be divided into two different lineages, based on Cluster of Differentiation (CD)-
3 expression: CD3- Natural Killer (NK) cells and CD3+ Cytotoxic T Lymphocytes (CTLs) 
[1,2]. The large majority of LGLs (85%) belong to the NK cells subset, which represents 
the main component of innate immune system and mediates a major histocompatibility 
complex (MHC)-non-restricted cytotoxicity. The other subset of LGL population 
(accounting for the remaining 15%), is represented by CTLs, which are the main 
component of the adaptive immune system and express a receptor (named T cell 
receptor, TCR) that recognizes the antigen (Ag)-MHC molecule complex on antigen 
presenting cells (APC) surface, mediating a “MHC-restricted cytotoxicity” [5]. 
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LGLs activation depends on antigen recognition, that leads to an approximately 50.000-
fold proliferation of these cells. In physiological condition, upon antigen clearance, 
activated LGLs are then eliminated through a process known as activation-induced cell 
death (AICD), which represents an important mechanism for the maintenance of 
immune homeostasis.  
An impairment of AICD process allows the maintenance of cytotoxic clones, since LGLs 
do not undergo apoptosis efficiently, leading to the development of a malignant 
condition, referred as Large Granular Lymphocyte Leukemia (LGLL) [6].  
1.2. Large granular lymphocyte leukemia 
1.2.1. Classification 
Large granular lymphocyte leukemia embodies a spectrum of rare lymphoproliferative 
disorders sustained by the clonal expansion of CTLs or NK cells in peripheral blood, which 
can infiltrate different organs, including bone marrow, liver and spleen [7]. 
The 2016 World Health Organization (WHO) included this disease among mature T and 
Natural Killer cell neoplasms, dividing it into three categories, according to the cell 
lineage and the clinical course of the disease [8]. These are: 
• T-Large Granular Lymphocyte leukemia (T-LGLL) 
• Chronic Lymphoproliferative Disorder of NK cells (CLPD-NK) 
• Aggressive NK leukemia (ANKL) 
T-LGLL and CLPD-NK share an indolent and chronic nature, with similar clinical and 
biological features. The discovery of the same genetic lesions, both in leukemic T-LGLs 
and NK cells, suggests a common pathogenetic mechanism that contributed to unify 
these entities, despite they arise from different cell lineages [9]. In contrast, ANKL is 
characterized by a highly aggressive clinical behavior [10], therefore it has been 
suggested to be a separate clinicopathologic entity within NK cells lymphoproliferations  
1.2.2. Epidemiology 
LGL leukemia accounts for 2% to 5% of chronic lymphoproliferative disorders in North 
America and Europe and for 5% to 6% in Asia [11]. Recently, the incidence of LGLL has 
been published from two registries, including data from the two biggest retrospective 
series.  
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The Dutch registry reported 0.72 cases per 1 million individuals per year, whereas the 
American registry found 0.2 cases per 1 million individuals per year. Remarkably, its 
incidence does not differ between male and female [12].  
LGLL is commonly diagnosed in elderly patients, with a median age of 66.5 at diagnosis. 
T-LGLL is the most frequent form of the disease, representing ∼85% of the cases, 
whereas CLPD-NK is estimated at <10% of cases [5]. ANKL, that is mainly seen in Asia, 
comprises <5% of the LGL disorders. It affects younger patients and is associated with 
Epstein-Barr virus infection [13]. 
1.2.3. Diagnosis 
LGLL diagnosis requires evidence of a chronic expansion of clonal LGLs, harboring a 
constitutive mature post-thymic phenotype, associated with an appropriate clinical 
context [1].  
First of all, diagnosis is based on the documentation of an increased numbers of 
circulating LGLs. Historically, the threshold of 2×109/L was mandatory. However, 
numerous patients present lower clonal expansion of LGLs, typically associated with 
cytopenias or autoimmune conditions. Thus, a threshold of 0.5×109/L is now generally 
accepted. Notably, the cytology of clonal LGLs is not different compared to their normal 
counterpart [12].  
Immunophenotype analyses have revealed that NK cells show a TCRαβ−/sCD3−/CD3ε+/ 
/CD4−/CD8+/CD16+/CD56+/CD57± phenotype. These cells represent a heterogeneous 
population that can be divided into two main subsets, based on the different density of 
expression of CD16 and CD56: CD56dim/CD16bright, which represent about 90% of NK cells 
in peripheral blood, and CD56bright/CD16dim/neg [14].  
Leukemic T-LGLs, instead, show a terminal effector memory phenotype, characterized 
by CD3+/CD4−/CD5dim/CD8+/CD27−/CD28−/CD57±/CD62Ldim/CD45RA+ expression[11]; in 
addition, T-LGLs can also express cytotoxic NK cell markers and receptor, including CD16, 
CD56, killer immunoglobulin–like receptor (KIR) and C-type lectin receptor, as the 
CD94/NKG2 heterodimer. A rare subset of leukemic T-LGLs can also be CD4+, with or 
without coexpression of CD8. CD4 and CD8 expression, indeed, identifies lineage with 
different functions.  
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The CD4 antigen is characteristic of T-helper lymphocytes, which represent a regulatory 
lymphocyte lineage, while the CD8 antigen is typical of cytotoxic T lymphocytes, which 
have effector functions [15]. Despite the expression of CD4, these cells can be classified 
as cytotoxic T lymphocytes.  
The clonal nature of T-LGLs expansion can be established through the detection of TCR 
rearrangement. T-LGLs typically harbor an αβ+ TCR a few, uncommon, T-LGLs can 
express a γδ+ TCR, but these cells are rarely detected. Clonality can also be assessed by 
flow cytometry, through the demonstration of a predominant TCR Variable β-chain (Vβ) 
family expression.   
To assess the clonality of NK cells, which instead do not express TCR, restricted 
expression of isoforms of killer immunoglobulin–like receptors has been used as a 
surrogate marker for clonal expansion [16]. 
1.2.4. Differential Diagnosis 
Many conditions can lead to the development of reactive LGLs proliferation, including 
splenectomy, solid organ or bone marrow graft, viral infections (human 
immunodeficiency virus, Epstein-Barr virus, cytomegalovirus), solid tumor and non-
Hodgkin lymphoma. In these cases, LGLs proliferations are typically poly- or oligoclonal, 
lasting only several months and are not responsible for cytopenias development. In 
difficult cases, bone marrow biopsy could be useful to define diagnosis, because in 
reactive LGL proliferation, bone marrow infiltration is generally absent [12]. 
1.2.5. Clinical manifestations 
Approximately one-third of patients are asymptomatic at diagnosis, whereas two-thirds 
of patients will become symptomatic during the course of the disease. Clinical 
manifestations include mainly cytopenias and autoimmune disorders [17,18].  
Neutropenia represents the most frequent clinical manifestation observed in LGLL 
patients: almost 85% of patients experience neutropenia and about 45% of them 
develop severe neutropenia. Therefore, initial presentation is often dominated by 
recurrent infections related to neutropenia, even if some neutropenic patients 
remained asymptomatic. Infections secondary to chronic neutropenia affect 15% to 39% 
of patients, involving primarily skin, oropharynx, and the perirectal area.  
 
 
9 
Severe septic complications may occur in about 5% to 10% of patients, representing the 
primary cause of related death [19,20]. 
Among cytopenias, transfusion-dependent anemia affects between 6% and 22% of 
patients according to series, and pure red cell aplasia occurs in 8% to 19% of cases. 
Thrombocytopenia, instead, is less severe and described in fewer than 20% of cases. 
A quarter of patients harbor splenomegaly, although hepatomegaly or 
lymphadenopathy is rarely observed.  
B symptoms and fatigue are rare and they are observed in only 20% to 30% of cases [12]. 
Remarkably, LGLL is commonly associated with autoimmune diseases, reported in about 
15% to 40% of patients. Rheumatoid arthritis is the most frequent and is present in 
about 15% of the cases. Autoimmune cytopenias are reported among 5% to 10% of 
patients. Systemic lupus erythematosus, Sjögren’s syndrome, autoimmune thyroid 
disorders, coagulopathy, and inclusion body myositis have occasionally been reported. 
Vasculitis with cryoglobulinemia was also reported. Moreover, cases of pulmonary 
artery hypertension considered as a vasculopathy with endothelial dysfunction were 
reported to be associated with LGLL [21,22]. 
Serum protein electrophoresis usually shows polyclonal hypergammaglobulinemia as a 
result of increased immunoglobulin G and/or A subclasses. Hypogammaglobulinemia is 
seen in 5% to 10% of patients. Defects in downregulation of immunoglobulin secretion 
in LGL leukemia could partly explain the development of autoantibodies and clonal B-
cell malignancies observed in this disease, monoclonal gammopathy of undetermined 
significance being the most frequent (10%–20%).  
Furthermore, chronic lymphoid leukemia, follicular lymphoma, mantle cell lymphoma 
and other neoplasia are also reported to be associated with LGLL [11,12]. 
1.3. Neutropenia 
Neutropenia is a reduction in the absolute neutrophils count (ANC) in the blood 
circulation and represents the most frequent cytopenia observed in LGLL patients.  
Neutropenia may be distinguished as: 
• mild neutropenia, with an ANC of 1.0-1.5 x109/L; 
• moderate neutropenia, with an ANC of 0.5-1.0 x109/L; 
• severe neutropenia, with an ANC lower than 0.5 x109/L.  
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The mechanism of neutropenia development in LGLL patients is not well understood 
and its pathogenesis is reported to be multifactorial, including both humoral and 
cytotoxic mechanisms [17,23]. Any acquired neutropenia may result from reduced 
and/or ineffective granulopoiesis and/or shortened neutrophil survival  
An alternative mechanism to account for neutropenia might be the impairment of 
granulopoiesis due to bone marrow (BM) infiltration by pathological LGLs [24,25]. 
However, in LGLL patients, it does not appear to be the major cause, as the analysis of 
the BM biopsy and aspirate in these patients usually reveals mild hypercellularity, 
whereas granulocytic progenitors are most often decreased and demonstrate a left-
shifted myeloid maturation. In addition, neutropenia is more common and more severe 
than anemia and thrombocytopenia. This observation supports the hypothesis that 
neutropenia could be due mainly to peripheral destruction.  
Consistently with this assumption, neutropenia may be due to splenic sequestration or 
destruction of neutrophils. However, although splenomegaly is documented in 20–50% 
of LGLL patients, there are no data to support a major pathogenetic role for 
hypersplenism in LGLs-associated neutropenia.  
LGLs isolated from healthy individuals were reported to suppress the growth of BM 
granulocyte–macrophage colony-forming cells. Nevertheless, coculture of leukemic T-
LGLs with BM derived from normal donors or with autologous BM, did not resulted in a 
significant inhibition of granulocyte– macrophage colony-forming cells. 
Several studies have also indicated the presence of antineutrophil antibodies in the sera 
of some neutropenic patients diagnosed with LGLL. However, in most of these cases, the 
possibility that the detected antibodies were anti-HLA antibodies, rather than true 
neutrophil autoantibodies, was not properly addressed. In addition, circulating immune 
complexes, which are more often present in the serum of LGLL patients, may limit the 
ability of tests to identify specific neutrophil autoantibodies. In a study, undertaken in 
five patients with T-LGL leukemia, the authors found low levels of immune complexes in 
only one patient and no definitive neutrophil autoantibodies in the remaining four 
patients. Collectively, immune-mediated destruction of neutrophils, via granulocyte 
antibodies and immune complexes, cannot be excluded [26,27]. 
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Among the cytotoxic mechanisms accounting for neutropenia development, also 
abnormal expression of KIR has been considered, since it has been demonstrated to be 
associated with pure cell aplasia [28]. 
However, the most supported mechanism accounting for neutropenia development is 
myeloid progenitor and neutrophil destruction via Fas-mediated apoptosis. Leukemic T-
LGLs, indeed, constitutively express FasL on their surface, in contrast to normal CTLs, in 
which FasL expression is consequent to their activation. Engagement of the death 
receptor Fas on the surface of target cells by FasL triggers apoptotic pathways [29].  
It has been established that mature neutrophils constitutively express Fas at higher 
levels than monocytes and eosinophils [30]. In addition, neutrophils have been shown 
to be more sensitive to Fas-mediated apoptotic cell death than monocytes or 
eosinophils. Although FasL is constitutively expressed on the surface of T-LGL leukemic 
cells, it can be shed in a soluble form (sFasL) by the action of metalloproteinases. 
Consistently, sFasL has been found markedly elevated in the sera of LGLL patients. 
Furthermore, sera from patients with T-LGL leukemia with elevated sFasL were shown 
to induce apoptosis in normal neutrophils in vitro and, remarkably, the clinical response 
to therapy for neutropenia in those patients was associated with a reduction in sFasL 
levels [31].  
Despite Fas is normally expressed by various hematopoietic cell subsets, normal CD34+ 
hematopoietic progenitor cells do not express this antigen under steady-state 
conditions. However, when CD34+ cells are cultured in the presence of TNF-α and/or 
ΙFN-γ, they show increased expression of functional Fas. Furthermore, CD34+ cells from 
patients with aplastic anemia, who have consistently elevated levels of TNF-α and ΙFN-
γ, upregulate Fas expression on CD34+ hematopoietic progenitors. Interestingly, 
lymphocytes from some patients with T-LGL leukemia spontaneously secrete IFN-γ and 
can also be induced to produce TNF-α. Based on these observations, it has been 
proposed that in T-LGL leukemia, TNF-α and IFN-γ, together with the overproduction of 
FasL, may induce Fas-mediated apoptosis of granulocytic progenitor. However, it has 
nott been clarified why the effects of these cytokines would concern only a specific 
lineage in T-LGL, whereas in aplastic anemia a broader suppression of hematopoietic cell 
subsets would occur [32], [33]. 
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1.4. Pathogenesis 
1.4.1. Etiology 
The etiology of LGLL still remains matter of debate, due to the fact that no single, specific 
agent but a series of events have a role in triggering LGLs proliferation [34]. Some reports 
strongly support the role of chronic antigenic stimulation by exogenous antigens, such 
as human T-cell lymphotropic virus (HTLV) or putative endogenous autoantigens as the 
initial stimulus inducing the activation and then the clonal expansion of effector LGLs 
[35].  
The exact role of retroviral infection as etiologic agent has not been entirely established. 
It has been described that most patients with LGLL are not infected with prototypical 
HTLV, however they showed serum reactivity against a small peptide derived from the 
HTLV-I envelope protein p21e [36]. 
1.4.2. Pathogenesis 
LGLL pathogenesis is still incompletely understood. The first step of LGLs proliferation is 
related to the chronic antigenic stimulation, which lead to a polyclonal expansion. Later, 
clonal proliferation and LGLs survival are sustained by interleukin (IL)–15 and IL-2 
proinflammatory cytokines and by platelet-derived growth factor (PDGF) (Figure 1.2). 
 
Figure 1.2. LGLL pathogenetic hypothesis.  
 
In addition, gene-profiling analysis has shown that leukemic LGLs are characterized by  
an upregulation of proapoptotic genes, whereas anti-apoptotic genes are reported to 
be downregulated. 
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A work of our lab has also shown a possible role for dendritic cells (DC) in the 
pathogenesis of LGLL. These cells belong to the antigen-presenting cell (APC) family, 
characterized by the ability to recognize antigens and later to present the same antigens 
and adhesion molecules on their surface to T cells, inducing their activation. DCs can be 
involved in LGLs proliferation after the recognition of a specific antigen that maintains 
proliferation by releasing cytokines like IL-2, IL-15 and IL-18. Immunohistochemical 
analysis performed on osteo-medullary biopsies of T-LGLL patients have shown the 
presence of direct contact between LGL and DC, in contrast to healthy controls, in which 
cells have a random distribution. Therefore, it has been hypothesized that the medullary 
environment represents the place where pathological proliferation starts and thus, DCs 
representing viral infection target cells. 
Another possible mechanism implicated in the inhibition of apoptosis is due to the 
resistance to Fas-mediated apoptosis. Leukemic LGLs, indeed, despite abundant and 
constitutive expression of Fas and FasL on thei surface, are resistant to Fas-mediated 
apoptosis. Interestingly, this cannot be attributed to dysfunctional Fas/FasL mutations. 
On the other hand, sera from LGL leukemia patients have been shown to contain 
elevated levels of a soluble form of Fas (sFas), which may act as a decoy receptor for 
FasL, thereby resulting in the Fas-resistant phenotype of leukemic LGLs. This resistance 
can also be partly attributed to impaired death-inducing signaling complex (DISC) 
formation. Normally, DISC assembly is the immediate downstream event of Fas–FasL 
cross-linking and is a prerequisite for Fas-mediated apoptosis. However, in leukemic 
LGLs, the overexpression of the DISC inhibitory protein FLIP is thought to impair DISC 
formation and thus prevent Fas-mediated apoptosis.  
Taken together, these mechanisms may account for the resistance of LGL cells to AICD 
mechanism. 
1.4.3. Dysregulated pathway 
A constitutive activation of different signaling pathways has been demonstrated in LGLs 
of patients, and significantly contribute to the escape of these cells from activation-
induced cell death (Figure 1.3) [37,38]. 
These include:  
 
 
 
14 
• JAK/STAT; 
• Fas/Fas Ligand 
• Nuclear factor (NF)-ĸB; 
• Ras/Mek/Erk; 
• PI3K/Akt; 
• Sphingolipid Rheostat. 
Among these, one of the most relevant is the JAK/STAT axis. 
 
Figure 1.3. Deregulated signaling pathways in leukemic LGLs. 
 
1.5. JAK-STAT pathway 
1.5.1. Regulation 
Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is a 
fundamental signaling cascade that transduces multiple signals from transmembrane 
receptors to the nucleus. The pathway is activated by the binding of a cytokine or a 
growth factor to its respective transmembrane receptors.  
Ligand binding induces the receptor dimerization/oligomerization. This leads to the 
activation of receptor-associated tyrosine kinases JAKs, which comprise four members: 
JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2).  
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JAKs activation leads to their cross-phosphorylation and to tyrosine phosphorylation of 
the cytoplasmic regions of the receptor with which they are associated.  
As a result, docking sites for downstream effector STAT proteins, containing 
phosphotyrosine recognition domains, are generated. STAT monomers are then 
recruited to the phosphorylated receptors, undergo tyrosine phosphorylation 
themselves and dimerize. The STATs dimers then translocate from the cytoplasm into 
the nucleus, where they regulate fundamental biological processes, by activating the 
expression of genes involved in cell differentiation, proliferation, inflammation and 
apoptosis (Figure 1.4) [39]. 
 
Figure 1.4. JAK/STAT signaling pathway. 
 
STAT proteins bind to tens of thousands of different sites in the genome, thereby they 
regulate the transcription of thousands of protein-coding genes, including oncogenes 
and tumor suppressors. Therefore, activity of the JAK-STAT pathway is finely regulated 
on multiple levels, to ensure suppression of signaling in the absence of cytokine 
recognition, but also to allow rapid, transient activation upon stimulation. This 
regulation is crucial, since a persistent activation of STAT proteins or an aberrant 
signaling might result in malignancies, autoimmune or inflammatory diseases.  
The JAK–STAT signaling can be regulated through different mechanisms, including the 
suppressor of cytokine signaling (SOCS) proteins and the protein inhibitor of activated 
STAT (PIAS) family, as well as various protein tyrosine phosphatases (PTPs) [40].  
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1.5.2. STATs proteins 
The mammalian family of STATs proteins consists of 7 members: STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b and STAT6.  
The STAT proteins share structurally and functionally conserved domains, including: a 
N-terminal domain, a coiled-coil domain, a DNA-binding domain (DBD), a linker domain, 
a Src-homology 2 (SH2) domain and a C-terminal transactivation domain (TAD) (Figure 
1.5). Among these, the SH2 domain mediates homo and heterodimer formation of STATs 
monomers [41]. 
 
Figure 1.5. Schematic representations of Signal transducer and activator of transcription (STAT) domains.  
 
Among the seven STATs members, STAT3 and STAT5b are the most significant in cancer 
development, whereas the other appear to have more limited roles in oncogenesis. 
Consistently, STAT3 and STAT5b constitutive activation have been found to be 
associated with initiation and progression of various cancers. The constitutive activation 
of these proteins can be the result of different aberrant mechanisms: increased 
upstream stimulation of kinases, lack of negative regulation or somatic activating 
mutations. Consistently, based on data collected from the Catalogue of Somatic 
Mutations In Cancer (COSMIC), STAT3 results the most frequently mutated gene from 
the STAT family in hematopoietic neoplasm, followed by STAT5b [42].  
1.5.3. STAT3 and STAT5b 
The STAT3, STAT5a, and STAT5b genes are located on the long arm of chromosome 17, 
in adjacent regions (17q11.2).  
STAT3 exists in two major isoforms: full-length STAT3α is 770 amino acids long, while 
the shorter form STAT3β, arising from an alternative mRNA-splice site at exon 23, gives 
origin to a protein in which the last 55 C-terminal amino acid residues are replaced by 7 
other residues. Thus, STAT3β lacks the TAD domain and seems to have specific functions 
of its own, as it can prevent the embryonic lethality of STAT3α-null mice and activate a 
set of STAT3 target genes.  
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STAT3 is essential for development, and total STAT3 ablation leads to early embryonic 
lethality in mice [43]. Targeted disruption of STAT3 function in mouse T-cells results in 
impaired IL-6-mediated survival and reduced proliferative response when stimulated 
with IL-2 [44], [45].   
STAT5a and STAT5b, instead, are separate genes. The coded proteins are 794 and 787 
amino acids long, respectively, and are over 90% identical at cDNA and protein level. 
STAT5b is required for the development and normal function of lymphocytes.  
Recent studies have shown that total STAT5a/b deletion in mice leads to high perinatal 
lethality, severe combined immunodeficiency, and a lack of lymphoid cells, further 
emphasizing the pleiotropic role of STAT5 proteins in immune system function [46,47].  
Stat5a-/- mice display impaired mammary gland development, whereas Stat5b-/- mice 
display impaired pituitary growth hormone production and consequently diminished 
body growth. Considering the function of the immune system, bone marrow derived 
macrophages of Stat5a-/- mice exhibit defective GM-CSF–induced proliferation and 
gene expression in addition to other immunological defects, including a reduced number 
of T and NK cells in vivo. The T-cell defect is associated with diminished IL-2–mediated 
signaling. Stat5b-/- mice present with a diminished absolute number of NK cells and a 
maturation block in bone marrow; the NK cell numbers are lower than in Stat5a-/- mice 
and NK-cell proliferation and cytolytic activity to IL-2 and IL-15 stimulation is poor. The 
T-cell defect is associated with diminished IL-2–mediated signaling [48]. 
1.5.4. STAT3 in LGLL 
STAT3 activation represents a hallmark of leukemic LGLs. Epling-Burnette et al., indeed, 
reported that leukemic LGLs constitutively express high levels of activated STAT3, 
compared to LGLs of healthy individuals [49].  
Several studies report aberrant mechanisms leading to STAT3 activation, including the 
presence of somatic activating mutations. Consistently, several STAT3 mutational 
hotspots have been detected in 30%-40% of T-LGL leukemia patients and in one-third of 
the CLPD-NK patients (Figure 1.6) [9,50].   
The most frequent are Y640F and D661Y, located in the SH2 domain, which promote the 
dimerization, phosphorylation and localization in the nucleus of STAT3 proteins.  
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Figure 1.6. Locations of STAT3 mutations and crystal structure of STAT3 homodimer. 
 
Anyway, in a study by Andersson et al, activating STAT3 mutations were also detected 
in the coiled-coil and DBD domains. Phenotypically, no difference was observed 
between patients with somatic mutations in the SH2 domain compared to those with 
mutations in the DBD and in the coiled-coil domain [51]. 
STAT3 mutations represent the most distinctive genetic lesions described in this disease. 
Despite their high mutational frequency, some studies question the role of these genetic 
lesions as the driver mutations in LGLL. For instance, it was demonstrated that 
expression of the STAT3 mutations were insufficient to induce LGL leukemia in mice 
models, and it was suggested that STAT3 mutations do not play a causal role in 
development of T-LGL leukemia and that additional gene mutations and deregulation of 
other signaling pathways, in association with STAT3 mutations, may cause T-LGL 
leukemia [52].  
STAT3 activation is also promoted by not-mutational mechanisms. Teramo A. et al., 
demonstrated that IL-6, which is the most important STAT3 activator, was highly 
released by LGLs-depleted PBMCs of patients, compared with healthy controls, 
suggesting that STAT3 activation may result from the persistent stimulation of this 
cytokine [53].  
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In addition, they provide evidence of a down-modulation of SOCS3 in leukemic LGLs, due 
to an epigenetic modulation, that leads to the lack of the physiological negative 
feedback mechanism controlling STAT3 activation [53].  
These two pathological mechanisms cooperate to maintain STAT3 activation even in 
STAT3 wild-type patients. Consistently, different studies have shown that almost all T-
LGLL patients are characterized by the activation of the STAT3 pathway, even without 
somatic mutations in the STAT3 gene. Andersson E. et Al. performed exome sequencing 
on 3 STAT3-mutation negative T-LGLL patients. They found an activated STAT3 pathway, 
by RNA expression and phospho STAT3 analysis, indicating that LGLL patients are 
characterized by the activation of STAT3 responsive genes even without the presence of 
somatic mutations in STAT3 gene [54].  
1.5.5. STAT5b in LGLL 
STAT5b mutations (Y665F and N642H) were initially found in a smaller subset (2%) of T-
LGLL patients, reported to have a distinctive immunophenotype (CD3+/CD8+/CD56+) and 
a clinically aggressive disease, with a poor prognosis [54]. Then, in a study by Andersson 
et al, STAT5b mutations were detected also in 55% of CD4+ T-LGLL patients. Based on 
these data, the authors concluded that STAT5b mutations are more unique, but not 
exclusive, for the CD4+ phenotype than for the CD8+ phenotype. Clinically, STAT5b 
mutated CD4+ T-LGLL patients show an indolent and asymptomatic disease, in contrast 
to the previous assumptions regarding the clinically aggressive disease observed in CD8+ 
T-LGLL patients harboring these genetic lesions [55].  
1.6. Treatment 
T-LGLL and CLPD-NK- share the same treatment options. Indications for treatment 
include moderate or severe neutropenia associated with recurrent infections, 
symptomatic or transfusion-dependent anemia, and associated autoimmune conditions 
requiring therapy.  
Guidelines for first line treatment in LGLL have not been established due to the lack of 
large prospective trials. First-line therapy relies on single immunosuppressive oral 
agents: methothrexate (MTX) (10 mg/m2 per week), cyclophosphamide (100 mg/d), or 
ciclosporin A (3 mg/kg per day) [12].  
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Treatment efficiency is reported by several retrospective series, but only a few 
prospective trials are available. First-line therapy results are detailed in Table 1.1 (only 
series including more than 10 patients are reported).  
 
Table 1.1. First-line therapy results. 
 
MTX and cyclophosphamide are the main immunosuppressive agents used for LGLL 
treatment. Overall response rates, however, ranges from 35% to 65%, and relapses 
frequently occur, due to the persistence of leukemic clone. 
Deep sequencing analyses of residuals LGLs clones reveals that cyclophosphamide may 
eradicate leukemic cells, providing durable response, whereas MTX and ciclosporin A 
treatment are associated with the persistence of leukemic clones.  These results remain 
to be validated in prospective trials.  
An important randomized trial (NCT01976182) investigating first-line MTX versus 
cyclophosphamide is ongoing in France and will hopefully determine the best choice of 
initial therapy in this disease [12]. Of interest was that STAT3 mutations at Y640F 
seemed to predict a response to methotrexate since all patients with this mutation 
better responded to this immunosuppressive agent [56].  
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2. AIM 
 
Large Granular Lymphocytes (LGLs) leukemia (LGLL) is a chronic lymphoproliferation of 
clonal T-LGLs or Natural Killer (NK) cells. Leukemic LGLs are characterized by the 
constitutive activation of JAK/STAT pathway, which is in part explained by the high 
frequency of somatic activating mutations in STAT3 and STAT5b genes.  
Neutropenia is the most frequent clinical manifestation observed in LGLL patients and 
represents a negative prognostic factor, since it might lead to recurrent infections. The 
mechanism leading to neutropenia development is still elusive, although literature data 
suggest that its pathogenesis could be multifactorial, comprising both humoral and 
cytotoxic mechanisms. One of most relevant hypotheses is the deregulated expression 
of Fas Ligand (FasL) by leukemic LGLs, since normal neutrophil survival is partly regulated 
by the Fas-FasL apoptotic system. Consistently, high levels of soluble FasL (s-FasL) have 
been detected in LGLL patients’ serum, likely triggering neutrophil apoptosis.  
The aim of this project were: i) to characterize neutropenic LGLL patients, identifying 
distinctive biological features that might become both a prognostic tool to recognize this 
high-risk category of patients and new potential therapeutic targets for neutropenia 
treatment; ii) to elucidate the molecular mechanism of neutropenia development, 
investigating the role of microRNAs, regarded as important gene expression 
regulators[57], often involved in the pathogenesis of cancer, in the regulation of sFasL 
expression. Therefore, considering the biological heterogeneity of the disease, we 
evaluated:  
• the immunophenotype of the leukemic clone, by flow cytometer analysis; 
• STAT3 activation level, by western blot assays; 
• STAT3 and STAT5b mutational status, by Sanger sequencing; 
• FasL transcriptional and protein levels, by Real Time-PCR and ELISA test; 
• Regulatory mechanism of FasL expression, by in-vitro inhibition and induction of 
STAT3 transcriptional activity; 
• miRNA pattern of expression in LGLs of neutropenic patients, compared to patients 
with normal neutrophil count, by a high throughput and single miRNA analysis. 
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3. MATERIALS AND METHODS 
 
3.1. Samples and ethical permission 
Samples were collected from 100 LGLL patients and 10 healthy donors. Patients referred 
to the Hematology and Clinical Immunology Division at the University of Padua and the 
diagnosis of LGLL was based on the WHO 2016 criteria. At the time of the study, none 
of them had received treatments.  
For some experiments, the Jurkat cell line was used. It is an immortalized T lymphocyte 
cell line that was established in the late 1970s from the peripheral blood of a 14-year-
old boy with T cell leukemia. 
All studies were conducted in accordance to the principles of the Helsinki declaration 
and written informed consents were obtained from all enrolled patients and healthy 
donors.  
3.2. Mononuclear cells separation  
Peripheral blood mononuclear cells (PBMCs) of patients and healthy donors were 
isolated from EDTA-treated peripheral blood by density gradient centrifugation with 
Ficoll-Paque PLUS (GE Healthcare Bio-Science; Pittsburgh, USA). This reagent is a 
sterile density gradient media for isolating mononuclear cells from human peripheral 
blood, using a centrifugation procedure based on the method developed by Bøyum. 
Ficoll-Paque PLUS was slowly added at the bottom of the tube in which peripheral 
blood was collected, up to ½ of the total blood volume. The tube was then centrifuged 
at 2200 rpm for 20 minutes. A stratification of different components was produced, 
obtaining plasma, lymphocytes, monocytes, platelets, Ficoll-Paque PLUS, granulocytes 
and erythrocytes (Figure 3.1). 
Red blood cells are efficiently aggregated by this agent at room temperature and collect 
as a pellet at the bottom of the tube. The layer immediately above the erythrocytes 
contains granulocytes. Lymphocytes, monocytes, and platelets, instead, are not dense 
enough to penetrate into the ficoll layer. Therefore, these cells collect as a concentrated 
band at the interface between plasma and the Ficoll-Paque PLUS and can be 
recovered with high yield in a small volume.  
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PBMCs are then subsequently washed and pelleted to removes platelets, any 
contaminating ficoll and plasma. The resulting cell suspension contains lymphocytes and 
monocytes and is suitable for further studies. 
 
Figure 3.1. Schematic representation of stratification of different components obtained by density 
gradient centrifugation with Ficoll-Paque PLUS.  
 
3.3. LGLs purification 
Leukemic CD57+ LGLs were purified from PBMCs of patients either by MACS separation 
or by sorting with the FACSAria III cell sorter (BD Biosciences, San Jose CA, USA).  
The normal counterpart of pathological T-LGLs, used as control and represented by 
CD3+CD8+CD57+ lymphocytes, was sorted from PBMCs of healthy donors.  
3.3.1. MACS separation 
CD57+ LGLs were magnetically labeled with MACS MicroBeads, conjugated to 
monoclonal anti-human CD57 antibodies (isotype: mouse IgM) (Miltenyi Biotec, Auburn, 
CA) and separated in a MACS column, placed in a MACS Separator. MACS® MicroBeads 
are 50-nm superparamagnetic particles, conjugated to highly specific antibodies against 
a specific cell surface antigen. Thanks to their small size, the beads do not activate cells, 
neither have to be removed for any downstream application.  MACS Column contain a 
matrix composed of ferromagnetic spheres covered with a cell-friendly coating. When 
the column is placed in a MACS Separator, the spheres amplify the magnetic field by 
10,000-fold, thus inducing a strong magnetic force within the column. The separation is 
based on three steps: magnetic labelling, magnetic separation and elution of labeled 
cells (Figure 3.2). After the labelling, cell suspension is applied onto the column and the 
magnetic field efficiently retains cells labeled with the nano-sized beads.  
900 x g 
20 minutes
Ficoll-Paque™ PLUS
Blood sample
Plasma, platelets
Mononuclear cells
Ficoll-Paque PLUS
Granulocytes, eritrocytes
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The flow-through fraction, depleted of the labeled cells, can be collected as the negative 
fraction, whereas the retained cells can be eluted, removing the column from the 
separator, as the positively selected cell fraction. 
 
Figure 3.2. Schematic representation of cell separation with MACS MicroBeads and columns.  
3.3.2. Sorting 
CD57+ T-LGLs were sorted with the BD FACSAria III cell sorter, which is a specialized flow 
cytometer with the ability to physically isolate cells of interest into separate collection 
tubes. The fluidics system of the sorter is responsible for moving particles from the 
sample injection chamber through the cuvette flow cell for interrogation (Figure 3.3).  
When a particle is detected and meets the predefined sorting criteria, an electrical 
charge is applied to the stream just as the droplet containing that particle breaks off 
from the stream. Then, the charged droplet passes by two strongly charged deflection 
plates.  
 
Figure 3.3. Schematic representation of cell sorting process with BD FACSAria III cell sorter.  
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Electrostatic attraction and repulsion cause each charged droplet to be deflected to the 
left or right, into a collection device, depending on the droplet’s charge polarity. 
Uncharged droplets are not affected by the electric field and pass down the centre to 
the waste aspirator. 
3.4. Flow Cytometry 
To characterize the immunophenotype of the leukemic clone and to verify the purity 
and the viability of the purified populations, samples were analyzed by Flow Cytometry, 
using a BD FACS CantoII analyzer and the BD FACS Diva software program (BD 
Biosciences). 
3.4.1. Flow Cytometry: principles and application 
Flow cytometry provides a multi-parametric analysis of single cells.  
A flow cytometer is provided with two detectors: forward scatter (FSC) and side scatter 
(SSC). The FSC is placed along the incident laser axis and measures the diffracted light, 
which is related to the cell size; the SSC, instead, is placed at 90° with respect to the 
incident ray and measures the reflected and refracted light, which is related to the 
internal complexity of the cell (Figure 3.4).  
 
Figure 3.4. Schematic representation of a flow cytometer.  
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From the contemporary analysis of the FSC and the SSC through a dot plot, it is possible 
to discriminate different cell populations, based on their morphological features (size 
and granularity). 
Several photomultiplier tubes (one for each type of emitted radiation) amplify the 
fluorescence signals emitetd by the cell-bound monoclonal antibodies, providing data 
on the positivity and the level of expression of specific surface markers.  
All information is then processed by a software.  
3.4.2. Monoclonal antibodies 
The immunophenotyping of PBMCs and purified T-LGLs were performed by staining with 
commercially available mouse monoclonal antibodies (mAbs) (Becton Dickinson, 
Sunnyvale, CA, USA), reported in Table 3.1.  
Antibody Clone Fluorescence 
anti-CD3 SK7 PE 
anti-CD4 SK3 FITC 
anti-CD8 RPA-T8 APC 
anti-CD16 B73 PE-Cy7 
anti-CD56 B159 PE 
anti-CD57 NK-1 FITC 
Table 3.1. Mouse monoclonal antibodies used in flow cytometry application. FITC: Fluorescein 
isothiocyanate; PE: Phycoerythrin; APC: Allophycocyanin; PE-Cy7: Phycoerythrin-Cyanine7. 
 
For quantitative determination of the TCR Vβ repertoire of T-LGLs, the IO Test Beta 
Mark TCR-Vβ Repertoire kit (Beckman Coulter, CA, USA) was used. The kit consists of 8 
vials containing mixture of conjugated TCR Vβ antibodies corresponding to 24 different 
specificities, covering approximately 70% of the normal human TCR Vβ repertoire.  
3.4.3. Annexin V/PI staining 
Cell viability was evaluated using the “FITC Annexin V Apoptosis Detection Kit with PI” 
(Immunostep, Italy).  
Apoptosis is a process characterized by a variety of morphological features. One of the 
earliest indications of apoptosis is the translocation of the membrane phospholipid 
phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane. 
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Once exposed to the extracellular environment, binding sites on PS become available 
for Annexin V, which is a 35-36 kDa, Ca2+-dependent, phospholipid binding protein with 
a high affinity for PS. As such, Annexin V can be conjugated to a fluorochrome, and used 
for the flow cytometric identification of cells in the early stages of apoptosis.  
The loss of membrane integrity, instead, is a process that accompanies the later stages 
of cell death, resulting from either apoptotic or necrotic processes. Therefore, staining 
with Annexin V is typically used in conjunction with a vital dye, such as propidium iodide 
(PI), for identification of early and late apoptotic cells.  
Viable cells with intact membranes exclude PI, whereas the membranes of dead and 
damaged cells are permeable to PI. Therefore, cells that are considered viable are both 
Annexin V and PI negative, while cells that are in early apoptosis are Annexin V positive 
and PI negative, and cells that are in late apoptosis or already dead are both Annexin V 
and PI positive. To asses cell viability of PBMCs or purified LGLs, 0.2x106 cells were 
washed in PBS to remove medium and resuspended in binding buffer. Annexin V-FITC 
was added and cells were incubated for 10 minutes at room temperature, in the dark. 
DNA was stained with PI immediately before proceeding with flow cytometric analysis. 
 
Figure 3.5. Schematic representation of AnnexinV/PI staining.  
3.5. Cell cultures 
PBMCs or LGLs of patients were cultured in RPMI 1640 medium (EuroClone, Italy) 
supplemented with: 2nM L-glutamine, 25 mM Hepes, 10% v/v of heated inactivated 
Fetal Calf Serum, 100 U/ml penicillin and 100 μg/ml streptomycin.  
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Cells were plated at a final concentration of 2×106 cells/ml and were maintained in 
incubator at 37°C in a modified atmosphere with 5% of CO2.  
The following treatments were employed:  
• Stattic (Selleckchem, USA), a STAT3 inhibitor;  
• Recombinant Human Interleukin 6 (Sigma-Aldrich, Steinhelm, Germany), a STAT3 
ativator.  
PBMCs or LGLs were then collected for protein and RNA extraction.  
Supernatants were collected and stored at -80°C for ELISA test.  
3.6. Proteic analysis   
3.6.1. Whole proteins extraction 
Freshly isolated cells or cells collected from culture conditions (0.25x106) were 
centrifuged at 5000 rpm for 5 minutes. Pellets were resuspended (1:1) in a Sample 
Buffer, Laemmli 2× Concentrates, which is a solution for denaturing and loading of 
protein samples in SDS-PAGE, composed of:  
• 4% SDS, which denatures the proteins and gives each an overall negative charge; 
• 10% 2-mercaptoethanol, which reduces the intra and inter-molecular disulfide 
bonds; 
• 20% glycerol, which increases the density of the sample; 
• 0.004% bromphenol blue, which serves as a dye front that runs ahead of the proteins 
and also serves to make it easier to see the sample during loading; 
• 0.125 M Tris HCl, pH 6.8.  
Protein samples were heated for 5 minutes at 100°C in in a heat block. Then, they were 
stored at -20°C for proteic analyses. 
3.6.2. SDS-PAGE 
Sodium Dodecyl Sulfate Poly-Acrylamide Gel electrophoresis (SDS-PAGE) is an analytical 
technique to separate SDS-treated proteins, based on their molecular weight. SDS is a 
detergent with a strong protein-denaturing effect which binds to the protein backbone 
at a constant molar ratio. In the presence of SDS and a reducing agent that cleaves 
disulfide bonds, critical for proper folding, proteins unfold into linear chains with 
negative charge proportional to the polypeptide chain length.  
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Acrylamide is used to prepare electrophoretic gels suitable for protein separation by 
size. Acrylamide mixed with bisacrylamide and with the polymerizing agent ammonium 
persulfate (APS) forms a crosslinked polymer network (polyacrylamide). The 
polymerization reaction is catalyzes by TEMED (N,N,N,N'-tetramethylenediamine). The 
size of the pores created in the gel is inversely related to the polyacrylamide percentage 
(concentration). Low-percentage gels are used to resolve large proteins, and high-
percentage gels are used to resolve small proteins. Negative charged denatured 
proteins, when placed in an electric field, will migrate towards the negative anode inside 
the poly-acrylamide gel.  
The gel typically consists of two sections: a “stacking” gel and a “separating” gel. The 
stacking gel has a low concentration of acrylamide (5%), that allows the proteins to be 
concentrated into one tight band before entering the separating gel. An acrylamide 
concentration between 10 and 15%, instead, was used for separating gel.  
Protein samples and a molecular weight reference (Seeblue Plus2 Prestained Standard 
1X, Invitrogen) were loaded into different wells in the stacking gel. They were separated 
using Amersham electrophoretic chambers, a specific saline running buffer (pH 8.3) 
(25mM Tris, 192mM glycine, 0.1% SDS) and an applied electric field of 25mA (Figure 3.6).  
 
Figure 3.6. Schematic representation of SDS-PAGE technique. 
 
3.6.3. Western Blotting 
After the electrophoresis, proteins must be transferred from the electrophoresis gel to 
a membrane, usually polyvinylidene difluoride (PVDF). In the transfer process voltage is 
applied to transfer the proteins from the gel to the membrane.  
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The setup includes sponges, filter papers, the gel, and the membrane, which is placed 
between the gel and the positive electrode (Figure 3.7). This ensures the migration of 
the negatively charge proteins from the gel to the membrane. The result is a membrane 
with a copy of the protein pattern that was originally in the gel. 
 
Figure 3.7. Schematic representation of the western blot sandwich. 
 
The transfer is performed in a specific saline buffer containing Tris 250mM, glycine 
1.92M and methanol 20%. Since PDVF membrane is highly hydrophobic, it must be pre-
wetted with methanol for 1 minute prior to submersion in transfer buffer. 
After the transfer, the membrane is saturated to prevent unspecific binding of the 
detection antibodies during subsequent steps. Saturation is performed for 1 hour in a 
solution composed of non-fatty milk 5% (Ristora) and TBS (Tris buffered saline) 
supplemented with Tween-20 0.05% (Sigma). Saturation is followed by washing in TBS 
plus Tween-20 0.05% in order to remove unbound reagents and reduce the background 
signal.  
The membrane is then incubated overnight at 4°C with a primary antibody that 
recognizes a specific protein or epitope on a group of proteins. The primary antibody is 
not directly detectable. Therefore, tagged secondary antibodies that recognize the 
heavy chains of the primary antibodies are used to detect the target Ag (indirect 
detection). Secondary antibodies are enzymatically labelled with Horseradish 
peroxidase. After a final series of washes to remove unattached antibodies, the 
antibodies on the membranes are ready to be detected.  
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An appropriate chemiluminescent substrate, which produces light, is then added to the 
membrane. The light output can be captured using ImageQuant LAS500 machine (GE 
Healthcare Life Sciences). As chemiluminescent substrates, Pierce ECL western blotting 
substrate (Thermo Scientific) and LiteAblot PLUS Enhanced Chemiluminescent Substrate 
(EuroClone) were used.  
In order to detect more antibodies with the same specificity and similar molecular 
weight it is necessary to strip the membrane. Stripping buffer reagent (Thermo 
scientific) allows the cleaning and the efficient removal of primary and secondary 
antibodies from immunoblots without removing or damaging the immobilized Ag. This 
allows blots to be re-probed with new antibodies. Membranes were covered with this 
buffer and incubated for 20 minutes at 37°C and then washed with TBS, afterwards the 
membranes were saturated again with milk. 
Primary antibodies: anti-phospho-STAT3(Tyr705) (Cell Signaling USA), anti-STAT3 (Cell 
Signaling USA); anti-β-actin (Cell Signaling, USA);  
Secondary antibodies: anti-rabbit IgG HRP-linked antibody (Cell Signaling, USA); HRP 
labeled goat anti-mouse IgG (KPL, USA). 
3.6.4. ELISA test 
To quantify sFASL concentration on plasma and supernatant of cell cultures, ELISA test 
has been used (eBioscience).  
The enzyme-linked immunosorbent assay (ELISA) is a tool that provides the quantitative 
detection of human sFASL present in biological fluids. The principles of the test are based 
upon the presence of an anti-human sFASL coating antibody that is adsorbed onto 
microwells, which binds the sFASL present in the sample or standard binds; a biotin-
conjugated anti-human sFasL antibody binds to human sFASL captured by the first 
antibody. Thus, Streptavidin-HRP binds to the biotin conjugated anti-human sFASL. 
Following incubation, unbound biotin conjugated anti-human sFASL and Streptavidin-
HRP are removed through a wash step. Substrate solution reactive with HRP is then 
added to the wells. The result is the formation of a coloured product in proportion to 
the amount of soluble human sFASL present in the sample. The reaction is terminated 
by addition of acid and absorbance is measured at 450nm. A standard curve is prepared 
from different human sFASL sample, with a known protein concentration.  
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3.7. Molecular analysis  
3.7.1. RNA extraction 
RNA was purified using RNeasy® Mini Kit (QIAGEN, Hilden, Germany), according to 
manufacturer procedures. This procedure combines the selective binding properties of 
a silica-based membrane with the speed of microspin technology.  
Biological samples are first lysed and homogenized in the presence of a highly 
denaturing guanidine-thiocyanate containing buffer, which inactivates RNases to ensure 
purification of intact RNA. Ethanol is then added to provide appropriate binding 
conditions of RNA to the RNeasy membrane. The sample is then applied to the RNeasy® 
Mini spin column, where RNA binds to the membrane, while contaminants are 
efficiently washed away. RNA is then eluted in RNase-free water and quantified using 
the NanoDrop™ 1000 Spectrophotometer (Thermo Scientific) (Figure 3.6). 
3.7.2. cDNA synthesis  
The reverse transcription from total RNA to complementary DNA (cDNA) was performed 
using the the Reverse Transcription System (Promega, Madison, WI, USA). The system 
uses a reverse transcriptase from Avian Myeloblastosis Virus (AMV), with an intrinsic 
RNase H activity, to synthesize single-stranded cDNA from total or poly(A)+ isolated 
RNA.  
The reaction mixture is composed as indicated in Table 3.2.  
Component Amount 
MgCl2, 25mM 4 μl 
Reverse Transcription 10X Buffer 2 μl 
dNTP Mixture, 10mM 2 μl 
Recombinant RNasin® Ribonuclease Inhibitor 0.5 μl 
AMV Reverse Transcriptase 15 u 
Oligo(dT) or Random Primers 0.5 μg 
Total RNA 1,5 μg 
Nuclease-Free Water to a final volume of 20 μl 
Table 3.2. Component of the reaction mixture. 
The reverse transcription was performed using a T100™ Thermal Cycler, with the 
following thermal protocol:  
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• 42°C for 15 minutes  
• 95°C for 5 minutes 
• 4°C maintenance  
Synthesized cDNA was then stored at -80°C and used for gene expression analyses.  
3.7.3. Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) 
The quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) is a method for gene 
quantification characterized by high sensibility and specificity. It is called “Real-Time 
PCR” because it allows to observe in real time the increase in the amount of DNA as it is 
amplified. This is possible because the qRT-PCR system combines a thermal cycler and 
an optical reaction module that detects and quantifies fluorophores. Molecules added 
to the PCR mix, as SYBR Green, bind the amplified DNA and emit a signal that increases 
in proportion to the rise of the amplified DNA products. An amplification curve is 
obtained, where cycle numbers are found in abscissa and the fluorescence normalized 
on internal fluorophore in ordinate (Figure 3.7).  
 
Figure 3.8. Schematic representation of a qRT-PCR reaction. 
At the beginning of the reaction there are only little changes in fluorescence and this is 
the baseline region; the increasing in fluorescence above this threshold underlines 
amplified product formation. From this point on, the reaction maintains an exponential 
course that degenerates in plateau at the end of the reaction. In the midway cycles the 
curve has a linear course: this is the most important phase since the amount of amplified 
DNA is correlated with the amount of cDNA expressed at the beginning in the sample. 
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In this linear region a threshold of fluorescence is chosen and from this value it is 
possible to obtain the Ct (threshold cycle), namely the number of cycles of amplification 
necessary for the sample to reach that threshold of emission.  
SYBR Green was used as detector dye: it emits low fluorescence if present in solution; 
on the contrary the signal becomes stronger if the dye binds to double strand DNA. 
However, SYBR Green is not a selective dye and binds to all DNA, even to primer dimers. 
For this reason, it is recommended the introduction of a further step after amplification, 
called dissociation protocol. During this step, temperature rises gradually until all the 
double strands are denatured.  
This method allows the identification of contaminants or unspecific amplification 
products since they show different melting points. Another dye, called ROX, works as an 
internal reference used by the instrument to normalize the SYBR Green fluorescence. 
For the evaluation of gene expression was used a relative quantification method. The 
original concentration (Co) of each sample was obtained using the following equation: 
Co=2-ΔΔCt, where: 
• ΔCt = Ct (target gene) - Ct (reference gene); 
• ΔΔCt = ΔCt (of sample) - ΔCt (of the internal calibrator, which is a sample used as 
reference and included in every reaction plate to compare different plates’ results); 
• 2-ΔΔCt (The “2”value represents the higher efficiency for reaction that means a 
doubling of the product at every cycle of amplification). 
The reaction mixture is composed as indicated in Table 3.3.  
Component Amount 
Roche FastStart Universal SYBR Green Master (ROX) 7.5μl 
Forward primer (5μM) 0,9 μl 
Reverse primer (5μM) 0,9 μl 
H2O 4.2 μl 
cDNA 1.5 μl 
Table 3.3. Component of the reaction mixture. 
FastStart Taq DNA Polymerase is a hot start polymerase with the following amplification 
protocol: 
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• UDG activation 50°C 2 minutes  
• Polymerase activation 95°C 10 minutes 
• Denaturation 95°C 15 seconds        x 40 cycles  
• Annealing and amplification 60°C 1 minutes  
Dissociation protocol: increasing temperature from 60°C to 95°C.  
The thermal cycler used was the Sequence Detection System 7000 (Applied Biosystem) 
and the software was ABI PRISM 7000. 
The primer used for amplification of genes of interest were designed by Primer express 
3.0 (Applied Biosystems).  
Their sequences are reported in Table 3.4. 
Gene target Forward primer Reverse primer 
FasL PT GCTGCCACCCCTGAAGAAG CCCTCCATCCCCTTATGCC 
FasL mRNA CCACCCCCTGAAAAAAAGGAG ATAGGTGTCTTCCCATTCCAG 
HuR TTTGGGCGGATCATCAACTC ATGGGCTCAGAGGAACCTG 
primiR-146b GAACGGGAGACGATTCACAG CCTTGGCATTGATGTTGTAGC 
GAPDH AACAGCCTCAAGATCATCAGC GGATGATGTTCTGGAGAGCC 
Table 3.4. Primer sequences designed for qRT-PCR. 
3.7.4. DNA extraction 
Genomic DNA extraction was performed using “Puregene Cell and Tissue” kit 
(Quiagen).  
Purified LGLs are lysed with an anionic detergent in the presence of a DNA stabilizer, 
that limits the activity DNases. RNA is then removed by treatment with an RNA digesting 
enzyme. Other contaminants, such as proteins, are removed by salt precipitation. 
Finally, the genomic DNA is recovered by precipitation with alcohol and dissolved in 
hydration solution (1 mM EDTA, 10 mM Tris·CI pH 7.5) (Figure 3.8). Purified DNA typically 
has an A260/A280 ratio between 1.7 and 1.9 and is up to 200 kb in size.  
DNA was quantified using the NanoDrop™ 1000 Spectrophotometer (Thermo Scientific) 
and then stored at –20°C, for mutational analyses. 
3.7.5. Sanger Sequencing 
STATs mutational analysis was performed on purified T-LGLs DNA. 
Sanger Sequencing is a multi-step process, consisting of: 
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• PCR of STAT3 gene exons 20-24 and STAT5b exons 16-17;  
• quality control of the amplified products by gel electrophoresis 
• purification of the amplified products by agarose gel band cutting  
• quality control by agarose gel electrophoresis 
• Cycle sequencing, using dye terminator technology  
• purification of Cycle-sequencing products using Dye-Ex columns Sanger-Sequencing 
In Sanger sequencing, the DNA to be sequenced serves as a template for DNA synthesis. 
A DNA primer is designed to be a starting point for DNA synthesis on the strand of DNA 
to be sequenced.  
Four individual DNA synthesis reactions are performed. The four reactions include 
normal A, G, C, and T deoxynucleotide triphosphates (dNTPs), and each contains a low 
level of one of four dideoxynucleotide triphosphates (ddNTPs): ddATP, ddGTP, ddCTP, 
or ddTTP. The four reactions can be named A, G, C and T, according to which of the four 
ddNTPs was included. When a ddNTP is incorporated into a chain of nucleotides, 
synthesis terminates. This is because the ddNTP molecule lacks a 3' hydroxyl group, 
which is required to form a link with the next nucleotide in the chain. Since the ddNTPs 
are randomly incorporated, synthesis terminates at many different positions for each 
reaction. Following synthesis, the products of the A, G, C, and T reactions are individually 
loaded into four lanes of a single gel and separated using gel electrophoresis, a method 
that separates DNA fragments by their sizes. The bands of the gel are detected, and then 
the sequence is read from the bottom of the gel to the top, including bands in all four 
lanes. For instance, if the lowest band across all four lanes appears in the A reaction 
lane, then the first nucleotide in the sequence is A. Then if the next band from bottom 
to top appears in the T lane, the second nucleotide in the sequence is T, and so on. Due 
to the use of dideoxynucleotides in the reactions, Sanger sequencing is also called 
"dideoxy" sequencing. 
3.8. miRNA analysis  
High throughput and single miRNA analysis were performed in collaboration with Prof. 
Bazzoni’s lab, by using the TaqMan® Human microRNA Array (v3.0, Panels A and B, 
Applied Biosystems) and the TaqMan® microRNA Human Assays (Applied Biosystems), 
respectively.  
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Array data were analysed by Gene Expression Suite software (Applied Biosystems) and 
Hierarchical Clustering Analysis (HCA) was performed by using Multi Experiment Viewer 
(MEV). miRNA expression values both from arrays and from single assays were 
calculated according to the comparative threshold cycle method using U6 as 
endogenous control. Relative miRNA expressions have been reported as fold change 
(FC). miRNAs samples with a FC>2 or FC<0.5 and P<.05 were considered as differentially 
expressed as compared to controls.  
3.9. Cell transfection  
Electroporation is a transfection technology based on the momentary creation of small 
pores in cell membranes by applying an electrical pulse.  
Cell transfection was performed in collaboration with Prof. Bazzoni’s lab, in Verona. 
Jurkat cells (106) or freshly purified CD57+ T-LGLs (107) were transfected with a miR-146b 
mimic (ID PM10105, Ambion, Applied Biosystems) or a Scrambled, using the Amaxa 
Nucleofector™ Technology (Lonza, USA) and the Ingenio Electroporation Solution (Mirus 
Bio), according to the manufacturer’s protocol.  
Transfected cells were plated in RPMI 1640 medium (EuroClone, Italy), supplemented 
as described above, for 24-48 hours before further analysis was done. 
 3.10. Statistical analysis  
Statistical evaluation was performed by using the Mann-Whitney U-test or Student t-
test, as appropriate, with α set to 0.05. Correlation coefficient was determined using the 
Spearman Rank Correlation. P<.05 were considered significant. Hierarchical Clustering 
Analysis (HCA) of TaqMan Human microRNA Array data was performed by using the 
Multi Experiment Viewer (MEV, mev.tm4.org/) software with the following parameters: 
Pearson Correlation and complete linkage. 
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4. RESULTS 
 
4.1. Characterization of neutropenic T-LGLL patients  
4.1.1. Evaluation of neutropenia  
In our cohort of 100 T-LGLL patients (50 males, 50 females), neutropenia, defined by an 
absolute neutrophil count (ANC) lower than 1.5 x 109/L, was documented in 39 out of 
100 patients (39%). Among these, 17 out of 39 (44%) presented also a severe 
neutropenia, with an ANC lower than 0.5 x 109/L.  
4.1.2. Immunophenotypic characterization of T-LGLs of neutropenic patients 
In order to define whether neutropenic patients share some phenotypical similarities, 
by flow cytometry analysis we performed a deep analysis of the immunophenotype of 
our cohort of patients.  
We observed that 68 out of 100 patients (68%) were characterized by CD3+/CD8+/CD4- 
T-LGLs expansion (defined as CD8+ T-LGLL), while the remaining 32 patients (32%) were 
characterized by CD3+/CD4+/CD8-/dim T-LGLs expansion (defined as CD4+ T-LGLL). 
According to the expression of CD16, CD56 and CD57, several possible 
immunophenotypic combinations were demonstrated in both CD8+ and CD4+ T-LGLL 
group (Figure 4.1).  
 
Figure 4.1. Immunophenotypes distribution analysis in T-LGLL patients. The graphs represent the 
incidence (%) of each immunophenotype in the group of CD8+ T-LGLL patients (pie chart on the left) as 
compared with the group of CD4+ T-LGLL patients (pie chart on the right).  
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In CD8+ T-LGLL patients the most common phenotype was CD16+/CD56-/CD57+ (37 out 
of 68, 54%), followed by CD16-/CD56+/CD57+ (17 out of 68, 25%), CD16-/CD56-/CD57+ (6 
out of 68, 9%), CD16+/CD56-/CD57- (4 out of 68, 6%), and CD16+/CD56+/CD57+ (4 out of 
68, 6%). In CD4+ T-LGLL patients, instead, only two phenotypes were observed: CD16-
/CD56+/CD57+ (25 out of 32, 78%) and CD16+/CD56+/CD57+ (7 out of 32, 22%). 
Interestingly, we observed that almost all neutropenic patients (38 out of 39, 97%) 
belonged to CD8+ T-LGLL subset, while among CD4+ T-LGLL group only one neutropenic 
patient (1 out of 32, 3%) was found, this last characterized by a mild neutropenia (ANC: 
1,47 x109/L).  
Remarkably, we observed that neutropenic patients share also the same CD16, CD56 
and CD57 expression pattern, being mainly characterized by CD8+/CD16+/CD56-/CD57+ 
phenotype (34 out of 39, 87%), followed by CD8+/CD16+/CD56-/CD57- (3 out of 39, 8%). 
In conclusion, the most frequent immunophenotype of neutropenic patients was 
characterized by the expression of CD8 and CD16 and by the concomitant absence of 
CD56 (37 patients out of 39, 95%). Only two neutropenic patients (2 out of 39, 5%) 
showed a different markers expression, being respectively CD8+/CD16-/CD56-/CD57+ 
and CD4+/CD8dim/CD16+/CD56+/CD57+ (Figure 4.2). 
 
Figure 4.2. Neutropenic patients’ immunophenotypes. The histogram represents the percentages of 
patients with neutropenia (ANC < 1.5 x109/L) subdivided according to their immunophenotypes. 
Neutropenia incidence resulted 95% in CD8+/CD16+/CD56- subset and 5% in the other immunophenotypic 
subsets (CD8+ T-LGLL and CD4+ T-LGLL, respectively). The difference is statistically significant (****P < 
0.0001, χ2 = 49.5 and χ2 = 55.7, respectively, using χ2 test).  
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Differently, the CD8+/CD16+/CD56- immunophenotype was rarely detected both in CD8+ 
T-LGLL and CD4+ T-LGLL patients with normal ANC (4 out of 61, 7%), proving to be a 
signature of neutropenic patients.  
Consistently, patients included in CD8+/CD16+/CD56- subset showed ANC value 
significantly lower than that observed in the remaining CD8+ subsets and CD4+ T-LGLL 
patients (mean ANC ± SEM: 0.795 ± 0.08 x109/L, 2.86 ± 0.22 x109/L, 2.6 ± 0.19 x109/L, 
respectively, P<0.05), confirming that this specific immunophenotype was significantly 
associated with the presence of neutropenia (Figure 4.3). 
 
Figure 4.3. ANC evaluation in the patients subdivided according to their immunophenotypes. Dot plot 
indicating ANC level of each patient. The mean of ANC ± SEM in CD8+/CD16+/CD56- subset (0.795 ± 0.08 
x109/L) is lower than in the other immunophenotypic subsets of CD8+ T-LGLL (2.86 ± 0.22 x109/L) and in 
CD4+ T-LGLL (2.6 ± 0.19 x109/L; *P < 0.05, using one-way Anova and Tukey’s multiple comparison test).  
4.1.3. Evaluation of STATs activation in T-LGLs of neutropenic patients 
STAT3 is reported to be constitutively activated in leukemic T-LGLs and to play a 
pathogenetic role in LGLL. To evaluate whether neutropenic patients were characterized 
by a major STAT3 transcriptional activity than the other T-LGLL patients, we evaluated 
STAT3 activation in T-LGLs of our cohort of patients.  
We measured, by western blot analysis, STAT3 phosphorylation at Tyrosine705 (p-STAT3-
Y705) and we observed a high p-STAT3-Y705 in T-LGLs obtained by neutropenic T-LGLL 
patients, belonging to CD8+/CD16+/CD56- subset. Conversely, a lower STAT3 activation 
was observed in T-LGLs from the other CD8+ subsets with normal ANC or in CD4+ T-LGLs, 
as compared to CD8+/CD16+/CD56- T-LGLs.  
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Consistently, the average values, evaluated by densitometric analysis on 26 
CD8+/CD16+/CD56- samples, resulted statistically higher as compared with all the other 
immunophenotypic subsets, evaluated on 23 samples (p-STAT3 Y705/STAT3, median ± 
SEM: 1.89 ± 0.78 and 0.49 ± 0.10, respectively, P < 0.01) (Figure 4.4).  
Taken together, our data showed that STAT3 activation clustered with 
CD8+/CD16+/CD56- phenotype and that neutropenic patients were characterized by 
higher levels of STAT3 activation as compared to the other T-LGLL patients. 
 
Figure 4.4. Evaluation of STAT3 activation. Western blot analysis on whole-cell extracts (0.25×106 CD57+ 
T-LGLs) purified from representative cases of T-LGLL patients, subdivided according to their different 
immunophenotypes are reported. Protein levels of p-STAT3-Y705 and total STAT3 are reported, β-Actin 
expression is shown as gel loading control. 
 
To evaluate whether the high levels of STAT3 activation observed in neutropenic 
patients could be explained by the presence of STAT3 mutations, we analyzed, by Sanger 
sequencing, STAT3 genetic lesions in our cohort of patients.  
Our data showed that 38 patients out of 100 analyzed (38%) carried STAT3 mutations. 
Among these: 24 cases out of 38 (63,2%) presented Y640F, 9 cases (23,7%) D661Y, one 
case (2,6%) D661V, one case (2,6%) N647I, one case (2,6%) with a hot spot mutation, 
K658R, together with an in-frame insertion, I659_M660insL, one case (2,6%) with an in-
frame deletion/insertion, A662_N663delinsH, and one case (2,6%) with an in-frame 
insertion, G656_Y657insY. 
We then evaluated the incidence of STAT3 mutations in our cohort of neutropenic 
patients. Interestingly, our data showed that almost all neutropenic patients (38 out of 
39, 90%) were STAT3 mutated (Figure 4.5). The correlation between the presence of 
STAT3 mutations and neutropenia resulted statistically significant (χ2=63, P < 0.001). 
Remarkably, all the patients experiencing severe neutropenia were included among the 
group of mutated cases.  
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Figure 4.5. Neutropenic patients subdivided depending on the presence/absence of STAT3 mutations. 
Among neutropenic patients (n=39), the histogram represents the percentage of patients with STAT3 
mutations (35/39, 90%) and wild type for STAT3 (4/39, 10%). The difference of neutropenia incidence is 
statistically significant (P < .001). 
 
According to a recent report showing high incidence (55%) of STAT5b mutations in CD4+ 
T-LGLL, we evaluated also the presence of these genetic lesions in our cohort of study. 
STAT5b mutations were found in 5 out of 100 patients (5%) and were represented by 
N642H (2 out of 5, 40%), Y665F (2 out of 5, 40%) and Q706L (1 out of 5, 20%).  
Accordingly to the data reported by Andersson et al., all patients harboring STAT5b 
mutations were affected by CD4+ T-LGLL, even if we observed a lower incidence of these 
genetic lesions (5 patients out of 32, 16%), as compared to the frequency reported in 
literature. None of them was neutropenic and neither show any clinical manifestation. 
Consistently, neutropenic patients did not show different level of STAT5b activation, 
compared to all the other CD8+ patients (data not shown). 
4.1.4. Evaluation of Fas Ligand expression in T-LGLs of neutropenic patients  
Soluble FasL, which is increased in the serum of LGLL patients as compared to normal 
donors, has been hypothesized to play a role in inducing neutropenia. 
Therefore, we evaluated FasL expression in our series of patients, subdivided according 
to their immunophenotype. We analyzed FasL transcriptional expression by Real-Time 
PCR, showing that it was higher in CD8+/CD16+/CD56- T-LGLL patients as compared to 
non-neutropenic patients belonging to the other immunophenotypes, both CD8+ and 
CD4+ T-LGLL (7.66 ± 0.87, 2.45 ± 0.22 and 2.35 ± 0.28 arbitrary units, respectively; P < 
0.001; Figure 4.6).  
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Figure 4.6. Fas ligand expression. Dot plots report Fas ligand mRNA transcription levels of T-LGLL patients 
subdivided according to their immunophenotypes. The means and SEM are reported. The expression level 
observed in the group of CD8+/CD16+/CD56- subset is higher as compared with the two other groups (***P 
< 0.001, ****P < 0.0001, using one-way Anova and Tukey’s multiple comparison test). 
 
The difference in FasL production, observed on transcriptional levels, was also 
confirmed by ELISA test, at protein levels, measuring sFasL level in patients’ plasma 
(CD8+/CD16+/CD56- T-LGLL: 88.3 ± 14.18 pg/ml, the other CD8+ and CD4+ 
immunophenotypes: 16.08 ± 14.62 pg/ml, P < 0.0001; Figure 4.7). 
 
Figure 4.7. Fas ligand expression. Dot plots report secreted Fas ligand plasma levels of T-LGLL patients 
subdivided according to their immunophenotypes. The means and SEM are reported. The expression level 
observed in the group of CD8+/CD16+/CD56- subset is higher as compared with the two other groups (***P 
< 0.001, ****P < 0.0001, using one-way Anova and Tukey’s multiple comparison test).  
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4.1.5. Molecular mechanisms involved in the regulation of Fas Ligand expression 
STAT3 is a transcription factor that promotes the expression of thousands of protein-
coding genes. To evaluate whether the high level of FasL transcription, observed in 
neutropenic patients, could depend on STAT3 activation, we inhibited with Stattic (a 
specific inhibitor of STAT3) or we triggered, with IL-6 (a key cytokine in LGLL 
development), STAT3 transcriptional activity.  
Our data showed that both p-STAT3-Y705 and FasL mRNA expression  slightly decreased 
after 2 hours treatment with Stattic (15 µM), as compared to the untreated conditions. 
On the contrary, when we triggered STAT3 activation with IL-6 (20 ng/ml), we observed, 
after 1 hour, an increase of p-STAT3-Y705, followed by an increase of 1.59-fold in Fas 
ligand transcription levels (Figure 4.8).  
To verify whether Fas ligand expression was modulated just by STAT3 activation, we pre-
treated patients’ PBMC for 1 hour with Stattic, before IL-6 incubation. Our data showed 
that Stattic was able to block IL-6 effect, by preventing p-STAT3-Y705 induction and, 
consequently, to prevent the increase in FasL transcription, both in STAT3 mutated and 
wild type patients. Therefore, we proved that STAT3 activation plays a crucial role in the 
regulation of FasL expression.  
 
Figure 4.8. FasL regulation. Western blot analysis and Real-Time PCR analysis of one representative out 
of six independent experiments are shown. Patient’s PBMC were cultured in the following different 
conditions: untreated condition (UT) for 2 hours; with Stattic (15 μM) for 2 hours; stimulated by IL-6 (20 
ng/ml) for 1 hour; pretreated for 1 hour with Stattic and then stimulated by IL-6 for 1 hour. On the top, 
protein levels of p-STAT3-Y705 and total STAT3 are reported, β-Actin expression is shown as gel loading 
control. The histogram on the bottom reports the average fold change of FasL mRNA levels. All the values 
were settled on untreated condition set at 1.0. Data are represented as mean ± SEM of six independent 
experiments. *P < 0.05 vs. UT; **P < 0.01 vs. IL-6 condition, using one-way Anova and Tukey’s multiple 
comparison test. 
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4.2. Characterization of neutropenic CLPD-NK patients 
4.2.1. Evaluation of neutropenia 
To characterized NK cells of neutropenic CLPD-NK patients, we performed the same 
studies in a cohort of 25 CLPD-NK patients. Neutropenia was detected in 10 out of 25 
patients (40%), with 5 patients out of 10 (50%) presenting severe neutropenia.  
4.2.2. Immunophenotypic characterization of NK cells of neutropenic patients 
By flow analysis, NK cells of patients were analysed for CD16 and CD56 expression, 
defining two major NK cells subsets, i.e. patients with CD56dim/CD16dim NK cells (4 out of 
25, 16%) and patients with CD56-/dim/CD16high NK cells (21 out of 25, 84%). Almost all 
neutropenic patients (8 out of 10, 80%) were included in CD56-/dim/CD16high subgroup. 
Considering the clinical heterogeneity of the CD56-/dim/CD16high subset, we then 
analysed the expression of CD57 on the cells of these patients, distinguishing two 
subgroups: patients characterized by a “cytotoxic” phenotype, defined by CD57 
negativity, and patients characterized by a “NK memory” phenotype, defined by CD57 
positive expression.  
Remarkably, all the patients who have experienced severe neutropenia presented a 
significantly lower CD57 mean expression as compared to the other CD56-/dim/CD16high 
patients (12.48% ± 2.87 vs 60.43% ± 4.38, p<0.0001) (Figure 4.9).  
 
Figure 4.9. CD57 expression levels. Dot plot indicating differential CD57 expression (%) in 
CD56dim/neg/CD16high subgroup between patients who experienced severe neutropenia (ANC < 0.5 x109/L) 
and patients who did not (ANC > 0.5 x109/L). As represented, patients with ANC < 0.5 x109/L presented 
CD57% expression significantly lower (p < 0.0001) toward patients with ANC > 0.5 x109/L. 
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4.2.3. Evaluation of STATs activation in NK cells of neutropenic patients 
We evaluated STAT3 activation in NK cells of our cohort of patients, but, differently from 
neutropenic T-LGLL patients, we observed a heterogeneous pattern of p-STAT3-Y705 
among our group of study (data not shown), with only 2 out of 25 patients (8%) 
harboring STAT3 mutations.  
Moreover, none of them harbored STAT5b mutations and we observed a heterogeneous 
level of STAT5b activation (data not shown).  
4.2.4. Evaluation of Fas Ligand expression in NK cells of neutropenic patients 
In leukemic T-LGLs, we demonstrated that FasL has a role in the development of 
neutropenia. Therefore, we analyzed, by Real-Time PCR, FasL transcriptional expression 
in NK cells of our cohort of patients.  
Herein,  the heterogeneity revealed in STAT3 activation levels was observed also in FasL 
expression (Figure 4.10). Therefore, our data, even if they were collected in a small 
cohort, do not demonstrate a clear role of FasL in neutropenia development in CLPD-NK 
patients.   
 
Figure 4.10. Fas ligand expression. Dot plot reports FasL transcription levels of CLPD-NK patients 
subdivided according to ANC values. The means and SEM are reported. The difference between the 
expression level observed in the two subsets is not statistically significant (P > 0.5). 
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4.3. Micro-RNA analysis 
4.3.1. Characterization of T-LGLs miRNome  
We demonstrated that the high levels of FasL detected in neutropenic T-LGLL patients 
were due to the high STAT3 activation that characterized the T-LGLs of these patients. 
However, the mechanism through which STAT3 regulates FasL production has not been 
clarified. Since many microRNAs (miRNAs) are regarded as important gene expression 
regulators, often involved in the pathogenesis of cancer, we investigated whether the 
increased FasL production was due to an altered expression of miRNAs.  
The miRNAs pattern of expression was investigated in a pilot cohort of patients, using 
Taq-Man Human microRNA Array. We assessed the expression of 756 mature miRNAs 
in CD57+ cells purified from 4 neutropenic CD8+/CD16+/CD56- T-LGLL patients, as 
compared to CD57+ cells purified from 2 CD4+ T-LGLL patients with normal ANC (Table 
4.1) and 3 healthy donors (HD).  
Patient ID T-LGLL T-LGLs phenotype ANC (x109/L) STAT3  
LGL 1 CD8+ CD3+/CD8+/CD16+/CD56-/CD57+ 0.95 Mut (Y640F) 
LGL 3 CD8+ CD3+/CD8+/CD16+/CD56-/CD57+ 1.43 WT 
LGL 5 CD8+ CD3+/CD8+/CD16+/CD56-/CD57+ 1.10 Mut (Y640F) 
LGL 9 CD8+ CD3+/CD8+/CD16+/CD56-/CD57+ 0.80 Mut (Y640F) 
LGL 10 CD4+ CD3+/CD4+/CD8-/CD16+/CD56+/CD57+ 5.70 WT 
LGL 17 CD4+ CD3+/CD4+/CD8-/CD16+/CD56+/CD57+ 2.29 WT 
Table 4.1. Biological and clinical features of T-LGLL patients studied. ANC: absolute neutrophil count; 
MUT: mutated; STAT3: Signal Transducer and Activator of Transcription 3; T-LGLL: T-large granular 
lymphocytes leukaemia; WT: wild type. 
 
Unsupervised Hierarchical Clustering Analysis (HCA) of normalized array data led to the 
identification of two clusters: cluster A, including the 4 neutropenic CD8+ T-LGLL patients 
(LGL 1, LGL 3, LGL 5 and LGL 9), and cluster B, including CD4+ T-LGLL patients (LGL 10, 
LGL 17) together with the 3 HD (HD1, HD2, HD4) (Figure 4.11).  
To confirm our previous observation, we evaluated STAT3 activation in whole-cell 
extracts obtained from CD57+ cells of patients and we observed that a STAT3 activation-
dependent/CD8+-specific miRNAs expression pattern was in place (Figure 4.12). 
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Figure 4.11. miRNome of T-LGLL patients. Heatmap representation of the 756 miRNAs analyzed. Results 
are expressed as arbitrary units (au) using U6 as reference control.  
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Figure 4.12. miRNome of T-LGLL patients correlates with STAT3 activation. Western blot analysis on 
whole-cell extracts (250×103 CD57+ T-LGLs) purified from the same cells as in Figure 4.10 were loaded on 
gels and immunoblots were performed.  Protein levels of p-STAT3-Y705 and total STAT3 are reported. 
 
4.3.2. CD8+ T-LGLs-specific miRNAs expression pattern  
We showed that CD8+/CD16+/CD56- T-LGLs expansion is often associated with 
neutropenia development. Therefore, to investigate whether microRNA could have a 
role in the pathogenesis of this cytopenia, we studied miRNAs differentially expressed 
in patients characterized by neutropenia as compared to patients with normal ANC.  
First of all, to get insights into the CD8+-specific miRNome, miRNAs expressed in CD8+ 
and CD4+ T-LGLs have undergone to differential expression analysis. miRNAs showing Ct 
value <32, and FC value >2 or <0.5 were considered as differentially modulated (Figure 
4.13).  
 
Figure 4.13. miRNAs differentially expressed in CD8 vs CD4 T-LGLs. Volcano plot showing miRNAs 
differentially expressed in CD8 as compared to CD4 T-LGLs. For each miRNA the –Log10 (P value) is plotted 
against the average Log2 (Fold Change). Vertical dashed lines represent the 0.5 and 2 boundary values for 
the Fold Change (FC), whereas the horizontal dashed line represents the .05 P value boundary.  
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Accordingly, twenty-four miRNAs emerged as up-regulated and only one miRNA, namely 
miR-146b, as down-regulated in a statistically significant manner (P<.05) in CD8+ as 
compared to CD4+ T-LGLs (Figure 4.14). 
 
Figure 4.14. miRNAs differentially expressed in CD8 vs CD4 T-LGLs. List of the 25 miRNAs significantly 
modulated: in green the down-regulated miRNA, in red the up-regulated miRNAs. FC and P by unpaired 
t-test are shown FC= fold change.   
 
4.3.3. Correlation analysis of miRNAs expression with ANC and STAT3 activation 
MiRNAs selected as differentially expressed in CD8+ and CD4+ T-LGLs were subsequently 
analyzed for correlation with the absolute neutrophil count (ANC) and STAT3 activation. 
Correlation analysis highlighted only two miRNAs, namely miR-630 and miR-146b, 
whose expression correlated with the absolute neutrophil counts (p= -0.886, P=.033 and 
p=0.866, P=.030, respectively) and simultaneously with the levels of p-STAT3 Y705 
(p=1.00, P=.003 and p=-0.866, P=.033, respectively) (Table 4.2).  
None of the remaining differentially modulated miRNAs correlated with the absolute 
neutrophil count of patients in a statistically significant manner.  
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 ANC STAT3-YP 
 p P p P 
hsa-miR-630 -0.866 .030 1.000 .003 
hsa-miR-146b 0.866 .030 -0.866 .033 
hsa-miR-939 -0.829 .058 0.943 .017 
hsa-miR-33a# -0.829 .058 0.943 .017 
hsa-miR-636 -0.829 .080 0.943 .017 
hsa-miR-1285 -0.657 .173 0.829 .058 
hsa-miR-1303 -0.600 .242 0.829 .058 
hsa-miR-623 -0.600 .242 0.829 .058 
hsa-miR-516-3p -0.543 .297 0.771 .103 
hsa-miR-566 -0.543 .297 0.771 .103 
hsa-miR-1233 -0.543 .297 0.771 .103 
hsa-miR-1247 -0.829 .059 0.657 .175 
hsa-miR-1267 -0.600 .240 0.657 .175 
hsa-miR-591 -0.543 .297 0.657 .175 
hsa-miR-1249 -0.600 .242 0.600 .242 
hsa-miR-484 -0.429 .419 0.600 .242 
hsa-miR-331-5p -0.429 .419 0.600 .242 
hsa-miR-197 -0.429 .419 0.600 .242 
hsa-miR-335# -0.486 .356 0.543 .297 
hsa-miR-571 -0.429 .419 0.543 .297 
hsa-miR-625# -0.486 .356 0.486 .356 
hsa-miR-1253 -0.486 .356 0.486 .356 
hsa-miR-1825 -0.371 .497 0.486 .356 
hsa-miR-501 -0.600 .242 0.429 .419 
hsa-miR-1227 -0.429 .419 0.429 .419 
Table 4.2. Correlation analysis of miRNA expression, Absolute Neutrophil Count and p-STAT3 Y705. 
Significant correlations (P<.05) are in bold. ANC: absolute neutrophil count; STAT3-YP: Signal Transducer 
and Activator of Transcription 3 phosphorylated at Tyr705. 
 
4.3.4. Validation analysis on miR-146b  
To validate the data collected in our pilot cohort, we performed a RT-qPCR single assay 
on T-LGLs purified from ad additional cohort of T-LGLL patients, confirming the 
downregulation of miR-146b expression in CD8+ T-LGLs, as compared to CD4+ T-LGLs 
(P<0.05) (Figure 4.15).  
Accordingly, a strong correlation between the expression of miR-146b and ANC 
(p=0.732, P=.002) (Figure 4.16) was demonstrated also in the validation cohort. 
Conversely, miR-630 was confirmed as differentially expressed in CD4+ T-LGLs as 
compared to CD8+ T-LGLs, but the correlation with ANC was not validated (data not 
shown). 
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Figure 4.15. miR-146b is differentially expressed in CD8+ vs CD4+ T-LGLs. miR-146b expression in each 
CD8+ and CD4+ T-LGLs together with mean ± SEM are shown. *  P<.05.  
 
 
Figure 4.16. Correlation analysis between miR-146b expression and ANC. miR-146b expression is 
reported as arbitrary units (au); ANCs are reported as cell*109/L. Spearman correlation coefficient (p) and 
P are reported. * P<.05 by Mann-Whitney U-test. 
 
4.3.5. Functional characterization of miR-146b 
To investigate miR-146b role in neutropenia development, we studied its effects on FasL 
expression. First of all, by RT-qPCR analysis,  we evaluated FasL transcriptional 
expression in T-LGLs of patients belonging to the validation cohort. According to our 
previous findings, we found that FasL mRNA expression was higher in neutropenic CD8+ 
T-LGLL patients (mean normalized expression 0.0306 ±0.0067) as compared to the non-
neutropenic patients belonging to the CD4+ T-LGLL subset (mean normalized expression, 
MNE: 0.0119 ± 0.0026, P=.02).  
Remarkably, no difference in the level of FasL primary transcript (FasL-PT) expression 
between CD8+ and CD4+ T-LGLs was observed (Figure 4.17).  
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This new evidence strongly suggested that a post-transcriptional mechanism controlling 
FasL expression was defective in CD8+ T-LGLL subset, resulting in increased FasL mRNA 
level. Taken together, these data hinted for a role of miR-146b in the regulation of FasL 
expression.  
 
Figure 4.17. miR-146b controls FasL mRNA expression. Correlation between miR-146b and FasL 
expression in CD8 and CD4 T-LGLs. The expression of miR-146b, FasL mRNA and FasL primary transcript 
(PT) (A) analyzed in additional CD8+ (n=7) and CD4+ (n=5) T-LGLs by RT-qPCR is reported as mean ± SEM. 
*P < .05; ns: not significant by Mann-Whitney U-test. 
 
In order verify this hypothesis, Jurkat cells were transfected with a miR-146b mimic. The 
levels of FasL mRNA expression were then analyzed 48 hours post transfection and our 
results showed that miR-overexpressing cells had reduced levels of FasL mRNA (MNE 
2×10-5 ± 5.77×10-6)  as compared to cells transfected with a scramble miRNA control 
(MNE 3.67×10-5 ± 6.67×10-6) (Figure 4.18). Conversely, restoration of miR-146b 
expression didn’t cause a significant reduction of FasL primary transcript expression.  
 
Figure 4.18. Jurkat cells were transfected with 75pmol miR-scr or miR-146b. 48h after transfection cells 
were processed and miR-146b and FasL mRNA expression were analyzed. Data are expressed as Mean 
Normalized Expression (MNE) relative to U6 (miR-146b) and GAPDH (FasL mRNA). Mean ± SEM of three 
independent experiments is shown. * P<.05, ns: not significant by paired t-test. 
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We then over-expressed miR-146b in CD8+ T-LGLs purified from patients. The 
restoration of miR-146b expression in these cells, as observed in the Jurkat cell line, 
caused a significant reduction of FasL mRNA, but not of primary transcript expression 
(Figure 4.19).  
Collectively, these data demonstrated that the loss of miR-146b was responsible for the 
increased FasL expression observed in CD8+ T-LGLs, and, consequently, of the related 
neutropenia. 
 
Figure 4.19. CD8 T-LGLs were transfected with 200pmol miR-scr or miR-146b. 24h after transfection cells 
were processed and miR-146b, FasL mRNA and PT expression were analyzed by RT-qPCR. Data are 
expressed as MNE relative to U6 (miR-146b) and RPL32 (FasL mRNA and PT). Mean ± SEM of two 
independent experiments is reported. 
 
4.3.6. HuR is target of miR-146b  
To experimentally demonstrate that FASL expression was regulated by miR-146b, in 
silico miR-target prediction analysis was performed by seven different target prediction 
software (microT4, miRanda, Pictar2, PITA, RNA22, miRWalk and TargetScan). However, 
target prediction algoritms did not identify FasL among the miR-146b putative target 
genes.  
Therefore, we supposed that FasL could be an indirect target of this miRNA and we 
studied wheter FasL transcription factors could be regulated by miR-146b. We found 
that several FASL transcription factors were predicted as miR-146b putative target genes 
(Figure 4.20), however we demonstrated that none of these was shown to be regulated 
by miR-146b (data not shown). 
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Figure 4.20. FasL transcription factors. Transcription factors that regulate FasL expression and evaluated 
as putative miR-146b targets. 
 
Thus, we checked for genes involved in FasL mRNA stability. Among the sixteen genes 
retrieved as putative miR-146b targets, commonly predicted by all softwares, only one, 
the ribonucleoprotein Human Antigen R (HuR), also known as ELAVL1, play a well-
defined role in mRNA stabilization, and has been reported to be absolutely required for 
FasL expression in T lymphocytes. Moreover, the potential miR-146b binding site in the 
3’ UTR of HuR (Figure 4.21-A) has been demonstrated to be functional.  
HuR mRNA expression levels were reduced in miR-146b overexpressing CD8 T-LGLs 
(Figure 4.21-B), thus demonstrating that HuR is target of miR-146b.  
 
Figure 4.21. (A) Base pairing comparison between mature miR-146b and HuR 3′UTR putative target site is 
shown according to microRNA.org (http://34.236.212.39/microrna/home.do). (B) CD8 T-LGLs were 
transfected with 200pmol miR-scr or miR-146b. 24h after transfection cells were processed and miR-146b 
and HuR mRNA expression were analyzed by RT-qPCR. Data are expressed as MNE relative to U6 (miR-
146b) and RPL32 (FasL mRNA and PT). Mean ± SEM of two independent experiments is reported. 
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4.3.7. Evaluation of HuR expression  
To confirm that HuR protein expression inversely correlates with the levels of 
endogenous miR-146b expression, we evaluated the intracellular levels of HuR protein 
in CD8+ T-LGLs as compared to CD4+ T-LGLs (Figure 4.21). Remarkably, endogenous HuR 
protein was detected in CD8+ T-LGLs at levels significantly higher (P=.003) than those 
detected in miR-146b-expressing CD4+ T-LGLs. Collectively, these data show that the lack 
of miR-146b unleashes the translation of HuR protein, that, in turn, stabilizes FasL mRNA 
leading to increased FasL production. 
 
Figure 4.22. HuR protein levels. The relative HuR protein levels, normalized for β-Actin, are reported as 
arbitrary units (au) below the Western blot. Mean ± SEM is shown (n=3), * P<.01 by unpaired t-test. 
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5. DISCUSSION 
 
In a large cohort of T-LGLL patients we showed that the CD8+/CD16+/CD56- 
immunophenotype and STAT3 mutations might have a prognostic value for the 
identification of patients characterized by neutropenia or more susceptible to its 
development. Moreover, we demonstrated the existence of a miRNA-FasL axis in 
leukemic T-LGLs, proving the role of miR-146b in neutropenia development through the 
modulation of FasL expression.  
The characterization of neutropenic CLPD-NK patients, instead, showed that they are 
characterized by CD56-/dim/CD16high/CD57- cytotoxic NK cells expansion. However, we 
observed a heterogeneous level of STAT3 activation and a heterogeneous expression of 
FasL in NK cells this subset of patients. 
LGL leukemia, indeed, is a biologically and clinically heterogeneous disease. From a 
clinical point of view, patients could be asymptomatic at the diagnosis, anyway most of 
them become symptomatic during the course of the disease. Neutropenia represents 
the most frequent clinical manifestation and, considering the role of neutrophils in 
bacterial defence, it represents a negative prognostic factor for patients, since it might 
lead to recurrent infections. LGLL is usually a clinically indolent disease, thus among all 
patients, only symptomatic ones require treatments, whereas all the others are usually 
followed by a watch-and-wait approach. For this reason, the identification of a 
phenotypic and molecular signature of neutropenic patients might become a useful 
prognostic tool to recognize this high-risk category of patients, who need to be followed 
with higher frequency than other low-risk patients, since they could develop symptoms 
related to neutrophils decrease.  
First of all, we observed that almost all neutropenic patients were diagnosed with the 
CD8+ subtype of T-LGLL, while only one patient was characterized by the less frequent 
CD4+ T-LGLs proliferation. Our data, reporting a normal neutrophil count in CD4+ T-LGLL 
patients, are consistent with the asymptomatic clinical behavior described for this T-
LGLL subtype[55] and address the clinical attention on CD8+ T-LGLL patients. However, 
not all CD8+ T-LGLL patients became neutropenic: within this T-LGLL category, indeed, 
different immunophenotypic subset could be recognized, based on the expression of T-
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LGLs surface markers. Remarkably, we demonstrated that the presence of neutropenia 
was mainly, but not exclusively, associated with the CD8+/CD16+/CD56- pattern of 
markers expression. Thus, our results show that already at diagnosis, the phenotypic 
analysis of leukemic clone might give information to identify patients who need further 
investigations. 
Our data showed that also STATs mutations could represent distinctive molecular 
features of neutropenic patients. These are the most distinctive genetic lesions 
described so far in this disease and represent a molecular marker with high specificity, 
although not exclusive, of LGLs lymphoproliferative disorders. STATs mutations do not 
affect all patients, but only a part of them and, differently from other hematological 
malignancies (i.e. BRAF mutations in Hairy Cell Leukemia), their clinical significance in T-
LGLL patients has not been clarified yet. In the literature, has been reported a correlation 
between the presence of STAT3 mutations and a more symptomatic disease, particularly 
with neutropenia [50,58], but these data were not confirmed by other authors. STAT5b 
mutations, instead, are reported to have different clinical impacts, depending on the 
immunophenotype of the mutated clone: they represent a signature of aggressive 
clinical course with a poor prognosis in CD8+ T-LGLL patients, while they are devoid of 
negative prognostic significance in CD4+ T-LGLL patients. 
Herein, we demonstrated that neutropenic patients were characterized by a high 
incidence of STAT3 mutations, as compared to other phenotypic subsets. Only one 
neutropenic patient, characterized by CD4+ T-LGLs proliferation, was devoid of STAT3 
mutation. STAT5b mutations, instead, were exclusively found in CD4+ T-LGLL patients, 
accordingly to data reported by Andersson et al. [55], moreover none of the STAT5b 
mutated patients was neutropenic, neither showed any clinical manifestation. Taken 
together, our findings suggest that the mutational status of the leukemic clone might be 
taken in account for the characterization of neutropenic patients and, more specifically, 
that STAT3 mutational analysis is highly recommended in CD8+/CD16+/CD56- patients. 
On the contrary, STAT5b mutational analysis do not represent a prognostic marker to 
identify patients susceptible to neutropenia development and is recommended only in 
patients with CD3+/CD8+/CD56+ phenotype, characterized by an aggressive subtype of 
T-LGLs proliferation.  
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Interestingly, our results contribute also to clearly separate CD4+ from CD8+ T-LGLs 
proliferations, accordingly to the different biological features, that we described in this 
work, characterizing these subtypes of T-LGLL.   
Consistent with the finding that STATs mutations promote the phosphorylation of STATs 
proteins, we observed high p-STAT3-Y705 in all neutropenic patients, suggesting that a 
strong STAT3 activation might represent another specific hallmark of this particular 
subset.  
To bridge the molecular features of neutropenic patients to the clinic, we then pointed 
our attention on the molecular mechanism of neutropenia development. The 
pathogenesis of this cytopenia, indeed, still needs to be established. Literature data 
suggest that it could be multifactorial, comprising both humoral and cytotoxic 
mechanisms [59]. One of the most relevant hypotheses might be the deregulated 
expression of FasL by leukemic LGLs, since normal neutrophil survival is partly regulated 
by the Fas-FasL apoptotic system [31]. Consistently, Liu et al. showed that neutropenia 
in LGL leukemia patients was consequent to the high level of soluble Fas ligand (sFasL) 
released by leukemic LGLs, likely responsible to trigger neutrophils apoptosis through 
Fas receptor.  
Here, we provide evidence that sFasL was specifically higher in neutropenic patients, as 
compared to other subsets and we demonstrated that FasL transcription was mediated 
by STAT3 activation, explaining why FasL was found to be more expressed in 
CD8+/CD16+/CD56- patients, who are specifically characterized by higher level of p-
STAT3-Y705.  
It is well known that FasL expression depends on post-transcriptional events. Important 
regulators of post-transcriptional modifications are microRNAs, that are small non-
coding RNA molecules able to bind target mRNAs, promoting their degradation or 
blocking protein translation [57]. Furthermore, microRNAs are often involved in the 
pathogenesis of a variety of conditions, such as cancer and autoimmunity. For instance, 
STAT3 directly activates miR-21, which is one of microRNAs with a role in promoting 
cancer cells survival and proliferation. 
Interesting insights come from the comparative analysis of the differentially expressed 
miRNAs within different T-LGLL subsets. The correlation analysis of miRNAs expression 
pattern with ANC of patients highlighted a strong and significant inverse correlation 
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between miR-146b expression and neutropenia. Consistently, miR-146b was found to 
be inversely correlated also with FasL expression. The restoration of the expression of 
this specific miRNA resulted in a significant reduction of the FasL mRNA expression level, 
which occurs in the absence of modification of the FasL primary transcript expression. 
Collectively, these data indicate that miR-146b affects FasL expression at a post-
transcriptional level. Nevertheless, in silico miR-target prediction analysis did not 
identify FasL among the putative miR-146b target genes, thus suggesting that miR-146b 
eventually affects FasL expression indirectly, by targeting genes involved in FasL mRNA 
stability. In fact, we demonstrated that the intracellular mRNA level of HuR (one of the 
sixteen genes retrieved as putative miR-146b targets independently predicted by seven 
miRNA-target prediction software) is affected by miR-146b over-expression. HuR, a 
ubiquitously expressed member of the HuR family of RNA-binding proteins, has a known 
role in mRNA stabilization and has been reported to be associated to the ARE-containing 
3’UTR of FasL mRNA, which is mandatory for its expression[60]. Remarkably, HuR has 
been experimentally validated as miR-146b target genes in glioma stem cells and 
endothelial cells, and the predicted miR-146b seed region located in the 3’UTR of HuR 
mRNA has been demonstrated to be functional. According to these published data, 
restoration of miR-146b expression in patients CD8+ T-LGLs decreases the levels of HuR 
mRNA and, consistently, of FasL. Noticeably, a statistically significant difference in the 
levels of endogenous HuR protein between CD8+ and CD4+ T-LGLs is detectable.  
Thus, by the evaluation of a relevant number of miRNAs, we identified a correlation 
between the miRNAs expression profile and individual T-LGLs population, characterized 
by a specific phenotype and by high levels of constitutive STAT3 phosphorylation. Our 
results, therefore, point to STAT3 activation as the most relevant factor, that drives the 
expression of CD8-specific miRNAs, in the pathogenesis of neutropenia. The 
pathogenetic mechanism that we propose is schematically represented in Figure 5.1. 
Further studies need to be performed to demonstrate the pathogenetic link between 
STAT3 activation and miR-146b defective expression. One hypothesis we are going to 
evaluate points to an epigenetic silencing of miR-146b promoter, mediated by STAT3, as 
reported in some neoplastic conditions[61,62]. Indeed, it was demonstrated that STAT3 
directly induces the expression of the DNA (Cytosine-5)-methyltransferase 1 (DNMT1) 
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in malignant T-cells and several studies have reported the central role of this enzyme in 
promoting DNA methylation and, thus, epigenetic gene silencing in cancer.  
Therefore, our future perspectives are the study of the methylation of miR-146b 
promoter and of the analysis of DNMT1 expression in these patients.  
 
 
Figure 5.1. Schematic representation of the molecular mechanism accounting for neutropenia 
development in T-LGLL patients. T-LGL: T-Large Granular Lymphocyte; FasL: Fas Ligand; sFasL: soluble Fas 
Ligand; HuR:Human Antigen R; 
 
In CLPD-NK, instead, the characterization of neutropenic patients highlighted that they 
represent a subset with distinctive feature, i.e. characterized by CD56-
/dim/CD16high/CD57- cytotoxic NK cells expansion. However, the heterogeneous level of 
STATs activation and the very low incidence of STATs mutations observed in these 
patients lead to hypothesise that different molecular mechanisms might play a role in 
neutropenia development in CLPD-NK. One of our future perspectives is the whole 
exome sequencing of NK cells of CLPD-NK patients, to identify new potential genetic 
lesions that might have a pathogenetic role also in neutropenia development.  
Thus, our results confirmed that CLPD-NK and T-LGLL are biologically different diseases 
and so further studies will be carried out to understand the pathogenetic mechanisms 
leading to neutropenia development also in these patients.  
In conclusion, this study, performed in a large cohort of patients, provides evidence for 
a link between biological markers (phenotype, STAT3 mutations and activation, FasL 
production) and neutropenia, confirming also the well-known heterogeneity of LGLL. 
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Moreover, our data emphasize the relevance of flow cytometry and STAT3 mutation 
analysis  to gain information on clinical course of disease.  
In addition, our extensive evaluation of miRNA landscape in T-LGLL patients indicates 
that miRNAs are likely involved in sustaining T-LGLs proliferation by contributing to 
amplify the signal along activating pathways involved in the pathogenesis of LGLL. 
Remarkably, for the first time the current study demonstrates a direct role of miR-146b 
in the development of neutropenia reported in a subset of LGLL patients, representing 
a potential target for individualized therapeutic approaches. 
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“…instead of the great number of precepts of which logic is composed, I believed that the four 
following would prove perfectly sufficient for me, provided I took the firm and unwavering 
resolution never in a single instance to fail in observing them.  
The first was never to accept anything for true which I did not clearly know to be such; that is to 
say, carefully to avoid precipitancy and prejudice, and to comprise nothing more in my judgement 
than what was presented to my mind so clearly and distinctly as to exclude all ground of doubt.  
The second, to divide each of the difficulties under examination into as many parts as possible, 
and as might be necessary for its adequate solution.  
The third, to conduct my thoughts in such order that, by commencing with objects the simplest 
and easiest to know, I might ascend by little and little, and, as it were, step by step, to the 
knowledge of the more complex; assigning in thought a certain order even to those objects which 
in their own nature do not stand in a relation of antecedence and sequence.  
And the last, in every case to make enumerations so complete, and reviews so general, that I might 
be assured that nothing was omitted”.  
 
 
Rene Descartes, 
“Discourse on the Method of Rightly Conducting One's Reason and of Seeking Truth in the Sciences” 
 
 
 
 
 
